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ABSTRACT 
 
THE DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF DIMERIC β-CARBOLINES 
BASED ON THE STRUCTURE OF NEOKAULUAMINE AND THE STUDY OF MANZAMINE A 
DIMERIZATION TOWARD NEOKAULUAMINE  
Jaruwan Chatwichien 
Jeffrey D. Winkler 
 
Neokauluamine, a naturally occurring dimeric ß-carboline alkaloid, was isolated from an Indo-
Pacific sponge (family Petrosiidae, order Haplsclerida) by Hamann et.al. in 2001. Neokauluamine 
exhibited improved antimarial activity in vitro and in vivo relative to currently available drugs 
artemisinin and chloroquine. Moreover, neokauluamine showed potent cytotoxicity against many 
types of human cancers including lung, colon and cervical cancers. Bases on the structure of 
neokauluamine, we designed, synthesized and evaluated simple dimeric ß-carbolines as lead 
structures for the development of biologically active compounds. Interestingly, the synthesized 
dimeric ß-carbolines exhibited antimicrobial activity and cytotoxicity against melanoma and lung 
cancer cell lines comparable to neokauluamine and its monomer, manzamine A. The cellular 
mechanism by which the dimeric ß-carbolines induce cell death in H1299 lung cancer cells was 
studied and it was found that the ß-carboline dimer accumulated in lysosomes and mediated 
apoptosis by upregulating a pro-apoptotic protein, PUMA (p53 upregulated modulator of 
apoptosis). The abundance of manzamine A relative to neokauluamine in Nature makes 
manzamine A an attractive starting material for the synthesis of neokauluamine. Recently, 
Tsukamoto et.al. discovered a novel manzamine alkaloid, pre-neokauluamine, as the key 
intermediate in the conversion of manzamine A to neokauluamine. Thus, we designed and 
synthesized a pre-neokauluamine-based model system to study optimal reaction conditions and 
selectivity of the key dimerization step. 
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CHAPTER 1. DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF DIMERIC ß-  
CARBOLINES BASED ON THE STRUCTURE OF NEOKAULUAMINE 
(Adapted with permission from Chatwichien, J., Basu, S., Murphy, M. E., Hamann, M. T. & Winkler, J. D. 
Design, synthesis, and biological evaluation of β-carboline dimers based on the structure of neokauluamine. 
Tetrahedron Lett. 56, 3515–3517 (2015), License number 3854361042387) 
 
1.1. Introduction 
ß-carboline alkaloids are a group of natural product that possess a tricyclic pyrido [3,4-
b]indole ring moiety.1 ß-carbolines can be prepared by Pictet-Spengler reaction of tryptamine (1) 
and aldehyde precursors (2) , as shown in Scheme1.1.1To date, more than one hundred ß-
carboline alkaloids have been isolated from a variety of terrestrial plants and marine sponges2 and 
exhibit a diverse range of biological activities including antitumor, antiviral and antimicrobial 
properties. For instance, Harman (7) and norharman (6) (Figure1.1) are the two most simple ß-
carboline alkaloids.  Both  are cytotoxic against several human tumor cell lines due to their ability 
to intercalate DNA and to disrupt enzymatic function.1  
 
 
Scheme 1.1 Formation of ß-carbolines from Pictet-Spengler condensation. 
2 
 
 
 
 
Figure 1.1 Examples of ß-carboline alkaloids. 
3 
 
Manzamines are a class of marine ß-carboline alkaloids that possess a fused and bridged 
tetra- or pentacyclic system attached to ß-carboline moiety.2 Over the last decades, more than 80 
manzamine alkaloids have been isolated.  They exhibit a broad range of biological activities 
including antitumor, antimalarial, antimicrobial, anti-Alzheimer, insecticidal, anti-inflammatory and 
anti-HIV/AIDS opportunistic infections.3 Baldwin and Whitehead proposed the biosynthesis of 
manzamine alkaloids via the key intramolecular Diels-Alder cyclization of the bis-dihydropyridine 
(23), derived from the simple building blocks; ammonia, C10 and C3 units, shown in Scheme1.2.4 
This hypothesis was later verified by the isolation of many manzamine-related alkaloids, such as 
ircinal A and keramaphidin B (21) that have similar structures to the proposed intermediates, and 
the biomimetic synthesis of keramaphidin B (21).5 
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Scheme 1.2 Proposed biosynthesis of manzamine alkaloids by Baldwin and Whitehead. 
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Manzamine A (10) is a representative member of the family of manzamine alkaloids. It was 
first isolated from marine sponges of the genus Haliclona by Higa et.al. in 1986, as a novel alkaloid 
that exhibited the growth inhibition of P388 mouse leukemia cells with an IC50 of 0.07 µg/mL.6 Due 
to the uniquely complex structure and interesting biological activity, manzamine A has been an 
attractive and challenging target for total synthesis7,8,9 and shows intriguing biological activity.1 
Manzamine A displayed in vitro cytotoxicity to a variety of human cancer cell lines including colon, 
lung and breast carcinoma cells. Moreover, manzamine A showed improvement in antimalarial 
activity both in vitro and in vivo over the clinically used drugs chloroquine and artemisinin.10,11 The 
structure-activity relationship (SAR) of manzamine A for antimalarial activity has been studied from 
its naturally occurring manzamine A-related alkaloids12 and its synthetic analogs3 and showed that 
the C-12 hydroxyl, the conformation of the eight-membered ring and the orientation of  ß-carboline 
are crucial for the activity. 
. 
Neokauluamine (16)10, a naturally occurring dimer of manzamine A, was isolated from an 
Indo-Pacific sponge (family Petrosiidae, order Haplsclerida) by Hamann et.al in 2001. Unlike the 
previously reported manzamine dimer, kauluamine, neokauluamine exhibited potent antimalarial 
activity in vitro and in vivo comparable to that of manzamine A. Moreover neokauluamine displayed 
two times greater cytotoxic against Hela cells and ca. 10 times more proteasome inhibitory activity 
than manzamine A.13  Since neokauluamine is relatively less abundant than manzamine A and 
other manzamines in Nature, we wanted to design and synthesize simple analogs of 
neokauluamine that retain the potent biological activity of the natural product.  
 
1.2. Design and synthesis of dimeric ß-carboline analogs 
The concept of polyvalency offers an attractive strategy for enhanced selectivity and 
binding affinity of polyvalent ligands to receptors relatively to their corresponding 
monomers.14Whitesides et.al. reported that a trivalent binding system of  vancomycin and D-Ala-
6 
 
D-Ala (DADA) has binding constant 25 times higher than biotin-avidin interaction, one of the 
strongest interaction in biological systems.15 Recently, our group has also reported that dimeric 
chloroquines exhibit higher autophagy inhibitor over a known monomeric antimalarial drug, 
hydroxychloroquine (HCQ).16 
 
Inspired by the dimeric structure of neokauluamine, we reasoned that the replacement of 
the complex central portion of the structure with linkers that could tether the two ß-carboline  
moieties in the relative orientation as in neokauluamine might retain the bioactivity of the natural 
product. While the published structure of neokauluamine, determined through NMR analysis, did 
not assign the stereochemistry at C-30’, C-31’, and C-34’,10 molecular modeling at the level of 
MMFF (SPARTAN v. 10.0, Wavefunction, Inc.) of each of the possible diastereomers revealed that 
the distance between the two ß-carboline moieties is ca. 13.8 Å for each of the possible 
diastereomers. The appropriate linker lengths were established using ChemBio3 Pro 13.0 by 
calculating the lengths of the extended conformations of commercially available or easily prepared 
diamines, the structures of which are shown in Figure 1.2.  
 
 Figure 1.2 Linkers varied in length and rigidity. 
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As shown in Scheme1.3, we envisioned that reductive aminations of β-carboline-1-
carbaldehyde (29) with diamine linkers would be an efficient way to put β-carbolines onto the 
diamine linkers to prepare the desired analogs. β-carboline-1-carbaldehyde (29) was prepared from 
tryptamine (1) in three steps according to a known procedure.17 The aldehyde 29 was then 
condensed with diamines 30-33 to form the corresponding Schiff base followed by reduction with 
sodium cyanoborohydride. Partial conversion to the dimers 25-28 resulted in the concomitant 
formation of corresponding monomeric ß-carbolines 34-36, which serve as important control 
compounds to test the importance of the dimeric structures for biological activity.  
 
  
Scheme 1.3 Synthesis of monomeric and dimeric ß-carboline analogs. 
 
 Substitutions on β-carboline have shown to have a significant impact on its biological 
activity.1 To screen for improved bioactive compounds, we prepared substituted dimeric β-carboline 
analogs from a variety of substituted β-carbolines (41) coupling with 2,2’-oxybis(ethylamine) (31) 
8 
 
which is one of the optimal linkers at the time, based on its antimicrobial activity and cytotoxicity. 
The substituted dimeric β-carboline aldehydes were prepared from commercially available 
substituted indoles, following a precedent literature.18 They then were tethered onto the diamine 31 
by reductive amination reaction, shown in Scheme1.4. 
  
Scheme1.4. Synthesis of substituted dimeric β-carboline analogs 
 
1.3. Biological evaluation of dimeric ß-carbolines 
1.3.1. Antimicrobial activities 
Infectious diseases such as HIV/AIDS, malaria and tuberculosis (TB) are a major cause of 
death worldwide.19 Most of the existing therapies for these diseases are either inefficient or yield 
severe side effects. The discovery of novel therapeutic agents is therefore urgently needed.  
Most of manzamine alkaloids have been reported to induce 98-99% inhibition of 
Mycobacterium tuberculosis (H37Rv) with MIC <12.5 µg/ml.10 Collaborating with Professor 
Hamann’s group at the University of Mississippi, we therefore evaluated the dimeric ß-carboline 
analogs for the inhibition activity against H37Rv and found that dimeric compounds 25-27 are 
comparable in their potency to manzamine A and significantly more active than the corresponding 
monomeric ligands. Interestingly, the rigid structure in dimeric ß-carboline 28 led to loss of 
biological activity. This suggests that the orientation of the two β-carbolines is crucial for biological 
potency, and that the more rigid linker excludes the necessary orientation between the two 
heterocycles. 
9 
 
 
 
H37Rv 
Compound  MIC [μg/ml] (%Inh) 
25 3 
26 1.3 
27 2.3 
28 >50 (23%) 
35 24 
36 17.8 
manzamine A (10) 1.5 
 
Table 1.1 Antituberculosis activity of manzamine A and ß-carboline analogs. 
 
 We further evaluated antibacterial activity of the prepared dimeric ß-carbolines and found 
that similar differences in the activity were observed between dimeric and monomeric β-carbolines 
against S. aureus, MRS, E. coli, P. aeruginsa and M. intracellulare. The only system that we 
examined for which this trend did not hold was P aeruginosa.   
 
 
IC50 (μM) 
Compound S aureus MRS E coli P aeruginosa M intracellulare 
25 1.5 2.14 10.27 12.11 5.99 
26 1.4 1.4 4.86 >20 3.15 
27 2.02 3.74 11.28 >20 9.1 
35 >20 >20 >20 >20 >20 
36 >20 >20 >20 >20 >20 
manzamine A (10) 0.9 1.3 - - 0.6 
 
Table 1.2 Antibacterial activity of manzamine A and ß-carboline analogs. 
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1.3.2. Cytotoxicity against cancer cell lines 
To study the biological activities of the prepared dimeric β-carboline analogs compared to 
the corresponding monomers and the natural products, neokauluamine and manzamine A, we 
examined their cytotoxicity against carcinoma cells which were sensitive to other β-carboline-
containing structures.20 In collaboration with Professor Murphy at the Wistar Institute, we tested the 
dimeric analogs against H1299 (lung) and A375 (melanoma) cancer cell lines as well as IMR90 
(normal lung fibroblast). The results are summarized in Table 1.3. We find that the dimeric β-
carbolines 25-27 are comparable in potency to both neokauluamine and manzamine A, and ca. 
10x more potent than the corresponding monomeric β-carbolines 34-36 and the more rigid linker 
analog, 28. The loss in potency of compound 28 again supported the importance of the orientation 
of the two β-carbolines in the dimers. A significant difference was also observed in the selectivity 
of these dimeric compounds for cancer vs. non-cancer cells. As indicated in Table 1.3, the 
selectivity index (SI) was ca. 10x greater for the dimeric compounds vs. the monomeric ligands 
against both cell lines.  
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IC50 (μM) SI 
Cell lines H1299 A375 IMR90 IMR90/H1299 IMR90/A375 
neokauluamine 1.7 N/A N/A     
manzamine A 1.9 4.9 79 41.2 16 
25 1.6 N/A N/A     
26 1.6 3 200.6 123.5 67 
27 1.8 2.2 127.7 69.1 58 
28 17.0 N/A N/A     
34 15.1 N/A N/A     
35 12.6 14.1 117.5 9.4 8 
36 14.5 24.1 181.3 12.5 8 
  
Table 1.3 Cytotoxicity (IC50) and selectivity index (SI) for manzamine A, neokauluamine, and 
dimeric and monomeric β-carboline analogs against H1299 (human non-small cell lung carcinoma 
cell line), A375 (human malignant melanoma) and IMR90 (human Caucasian fetal lung fibroblast). 
 
To screen for more potent biologically active compounds, we prepared dimeric substituted 
β-carboline compounds in which the linker is 2, 2’-oxybis (ethylamine) (31) (Figure1.3). The 
cytotoxicity against H1299 cells was evaluated and the results are summarized in Figure1.3. 
Unfortunately, most of them showed similar activities to the corresponding dimeric unsubstituted ß-
carboline, 26, with no significant improvement in potency. 
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Figure 1.3  Cytotoxicity (IC50) for dimeric and monomeric substituted β-carboline analogs against 
H1299 (human non-small cell lung carcinoma cell line). 
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According to the World Health Organization (WHO), lung cancer is one of the most 5 
common types of cancer in both men and women and the leading cause of cancer deaths 
worldwide.21 Lung cancer is traditionally categorized into two major types; small cell (SCLC) and 
non-small cell (NSCLC) lung cancer. Most lung cancers are NSCLC (85%) and very challenging to 
treat due to acquired resistance. With currently available drugs for the treatment of NSCLC, the 5-
year survival rate is still less than 15%. The development of novel and more effective 
chemotherapeutic agents is therefore necessary.  
 
 Since the dimeric β-carboline analogs 25-27 displayed potent cytotoxicity against H1299 
(human non-small cell lung carcinoma cell line), we decided to study the cytotoxicity of the dimeric 
β-carbolines against other NSCLC cell lines. Compound 25 was evaluated for cytotoxicity against 
another five NSCLC cell lines (A549, H441, H1373, H1993 and H2009). As observed previously, 
dimeric β-carboline 25 exhibited comparable potency to manzamine A and was significantly more 
potent than its monomer 34 in all indicated NSCLC cell lines. This result supports the importance 
of the dimeric β-carbolines, and their potential utility as the starting point for the development of 
antitumor agents.  
 
compound 
IC50 (μM) 
A549 H441 H1373 H1993 H2009 
manzamineA 2.3±0.5 1.1±0.1 2.1±0.1 3.9±1.7 1.6±0.2 
25 2.9±0.8 0.7±0.3 3.3±2.1 1.2±1.1 1.4±0.2 
34 20.5±9.2 4.3±2.8 13.2±0.3 9.3±7.1 8.9±0.1 
 
Table 1.4 Cytotoxicity (IC50) for manzamine A, dimeric β-carboline (25) and monomeric (34) β-
carboline against NSCLC. 
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1.4. Cellular mechanism of dimeric β-carboline (25) induced cell death in H1299 cells 
Due to the striking activity of the simple synthetic dimeric β-carboline structures that 
exhibited similar cytotoxicity against cancer cells to the natural products manzamine A and 
neokauluamine, we were motivated to investigate the mechanism of dimeric β-carbolines to 
induction of cell death. As a preliminary study, we studied the mechanism of cell death with 
compound 25 (one of the most potent dimeric β-carboline analogs) along with manzamine A and 
its monomer (34), served as the controls, in H1299 cells.  
 
Lysosome, a membrane-bound organelle that contains different types of acidic hydrolases, 
has emerged as an interesting target to induce cancer cell death.22 Lysosome is a key component 
in autophagy. When fuse with autophagosomes, lysosome dispenses its enzymes into the 
autophagic vesicles to digest cellular unwanted materials.23 The environment inside is usually 
maintained acidic by a vacuolar ATPase as a proton pump transferring protons from cytosol into 
lysosomal lumen.24Lysosomal dysfunction due to vacuolar ATPase inhibition and interior pH 
elevation impairs autophagy and consequently activates apoptosis.25 Moreover, losing lysosomal 
membrane integrity renders lysosomal membrane permeabilization (LMP). In case of moderate 
lysosomal destruction, LMP mediates caspase-dependent apoptosis via the leakage of cathepsins 
into cytosol. Moreover, when massive lysosomal damage occurs, necrotic cell death is induced.26 
 
Manzamine A25, chloroquine27,28and Lys0516 have been reported as lysosome-targeting 
anticancer agents. Due to their weakly basic property (pKa = 9.2, 10.1 and 8.4, respectively), they 
are protonated and trapped in the acidic interior of lysosomes. The accumulation of these weak 
bases enhances the interior pH, causing inhibition of hydrolase activities and consequently 
autophagy inhibition.  
 
To study the cellular mechanism of dimeric β-carboline 25 induced cell death, we first 
determined the localization of the compound at the subcellular level. Taking advantage of the 
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inherent fluorescent properties of the β-carboline moiety (Ex/Em: 358/461 nm), we treated H1299 
cells with compound 25, 34 and manzamine A for 1h before staining mitochondria with 
MitoTracker® Green FM (Invitrogen) and lysosomes with LysoTracker® Red DND-99 (Invitrogen). 
As expected by the weakly basic property of the compounds (25; pKa= 8.2 and 34; pKa = 8.1), live 
confocal microscopy demonstrated that each of the compounds predominantly localized in 
lysosomes. These observations are similar to the finding seen previously for manzamine A that is 
known to target vacuolar ATPases in lysosomes and inhibits autophagy by preventing 
autophagosome turnover in pancreatic cancer cells.25 To investigate whether compounds 25 and 
34 lead to the same effect as was observed with manzamine A, we performed western blot analysis, 
probing for autophagy markers (LC3 and p62/SQSTM1). H1299 cells treated with dimeric β-
carboline 25 showed an increase in autophagy adaptor protein, p62/SQSTM1, and a dose-
dependent increase in LC3II levels, compared to the control DMSO. To further confirm these 
findings, we examined LC3II puncta by immunofluorescence studies for GFP-LC3 in H1299 cells 
transfected with GFP-LC3. Similar to western blot analysis, the transfected cells treated with β-
carbolines and manzamine A showed an increase in LC3II puncta, indicating a decrease in 
autophagosome clearance.  
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Figure 1.4 H1299 cells were treated with compound 25, 34 or manzamine A for 1h before staining 
mitochondria with MitoTracker® Green FM (Invitrogen) and lysosomes with LysoTracker® Red 
DND-99 (Invitrogen). Confocal analysis showed localization of the β-carboline compounds in 
lysosomes. 
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Figure 1. 5 a) Western blot analysis of LC3 and p62 in H1299 cells treated with DMSO, compound 
34 (20 μM), compound 25 (3, 5 and 10 μM) or manzamineA (10 μM) for 24 h incubation. b) GFP-
LC3 transfected H1299 cells were treated with DMSO, compound 34 (20µM), compound 25 (3, 5 
and 10µM) or manzamineA (10µM) for 24h. The GFP-LC3 puncta were analyzed by confocal 
microscope. c) Number of punta/cell was scored by ImageJ software. n=30; error bars, s.d. 
a) b) 
c) 
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Apoptosis and autophagy cross-regulate each other. 29,30,31 Autophagy inhibition was 
reported to induce apoptotic cell death.32,33,34 To determine if the dimeric β-carboline (25) induces 
cell death in H1299 cells through apoptosis, we examined Annexin positive cells using the Guava 
Nexin reagent. H1299 cells were treated with either compound 25 or compound 34 for 48h before 
staining with Annexin V-PE and 7-AAD. Flow data analysis for the number of apoptotic cells showed 
that the dimeric β-carboline (3 µM) induced significant increase in apoptotic cell death compared 
to the monomer (15 µM), (Figure 1.6). Similarly, dimeric β-carboline (25) induced significant 
increase in cleaved caspase 3 expression in a dose-dependent manner as seen by western blot 
analysis (Figure 1.7a) and immunofluorescence (Figure 1.7b). Other apoptotic markers such as 
cleaved lamin A and cleaved PARP levels were upregulated with dimeric β-carboline (25) 
compared to the monomer (Figure 1.7a). These results suggest that the dimeric β-carboline (25) 
induces cell death through caspase-dependent apoptosis more efficiently than its monomer. 
. 
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Figure 1. 6  H1299 cells were induced to undergo apoptosis by incubation with DMSO (control 
experiment), compound 34 (15 µM) and compound 25 (3 µM) for 48 h. After incubation, cells were 
stained with Guava Nexin Reagent, and data acquired on the PCA-96 System. The results showed 
4%, 11% and 97% apoptotic cells, respectively. n=3; error bars, s.d. 
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Figure 1. 7 a) Western blot analysis of apoptotic proteins in H1299 cells treated with DMSO, 
compound 34 (20 μM) and compound 25 (3, 5 and 10 μM) for 24 h incubation. b) Confocal 
immunofluorescent analysis for active caspase 3 of H1299 cells treated with DMSO, compound 34 
(20 μM), compound 25 (5 μM) for 24 h incubation. c) Apoptotic cells were quantified from the ratio 
of number of cell expressing active caspase to total cell number, n=3; error bars, s.d. 
 
a) b) 
c) 
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To further investigate the mechanism of induced cell death with dimeric β-carboline (25), 
we performed western blot analysis to detect proteins that are involved in the apoptotic pathway. 
Our previous experiments suggested that dimeric β-carboline (25) accumulated in lysosomes and 
mediated caspase-dependent apoptotic cell death. We therefore elected to further investigate the 
relationship between lysosomal dysfunction and caspase-mediated cell death. Many recent studies 
have demonstrated the crosstalk between autophagic and apoptotic pathways.31 Several BH3-only 
proteins are known to play dual roles in the regulation of these pathways. PUMA (p53 upregulated 
modulator of apoptosis), in particular, mediates caspase cleavage by either activation of Bax/Bak 
or inhibition of antiapoptotic proteins.35 Recent studies have shown that autophagy inhibition 
upregulates PUMA expression.32 Interestingly, western blot analysis of H1299 cells treated with 
different concentrations of dimeric β-carboline (25) showed a dose-dependent increase in PUMA 
level, corresponding to the cleaved caspase 3 level observed previously. To determine whether 
dimeric β-carboline (25) induced PUMA expression at the transcription level, we performed qRT-
PCR analysis and found that the PUMA mRNA levels in H1299 treated with dimeric β-carboline 
increased in a dose- and time-dependent manner, consistent with PUMA protein levels. Besides 
p53, PUMA expression can be regulated by other transcription factors (e.g. p73 and E2F1) 
depending on stimuli and cell lines.35 Since H1299 is a p53 null cell line, these data suggests that 
dimeric β-carboline (25), by accumulation in lysosomes, may be involved in a mechanism that 
affects p53-independent regulation of PUMA expression and consequently mediates caspase-
dependent apoptosis. 
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Figure 1.8 a) Western blot analysis of PUMA in H1299 cells treated with DMSO, compound 34 (20 
μM) or compound 25 (3, 5 or 10 μM) for 24 h incubation. b) RNA was harvested after 8 and 24 
hours after treatment with DMSO, compound 34 (20 µM) or compound 25 (3 or 10 μM). PUMA 
expression was analyzed by qRT-PCR. Expression was normalized to 18S levels and is reported 
as fold increase over untreated control. 
b) 
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1.5. Discussion 
Inspired by the naturally occurring dimeric β-carboline, neokauluamine, the dimeric β-
carboline analogs were prepared and demonstrated interesting biological activities including 
antimicrobial and anticancer properties. The dimeric compounds 25-27 exhibited comparable 
potency to the natural products manzamine A and neokauluamine and were significantly more 
potent than their corresponding monomers. The more rigid molecule (28) showed decreased 
potency compared to the flexible dimeric analogs, suggesting that the activity is dependent on the 
orientation of the two β-carboline moieties. 
 
Substitutions have shown to affect biological activities of β-carboline compounds.1 
However, in our experiments, the substituents on dimeric β-carboline demonstrated no effect on its 
cytotoxicity against a human lung cancer cell line (H1299). 
 
The interesting biological activities of dimeric β-carboline (25) against various NSCLC cell 
lines led us to further study its cellular mechanism to induce cell death in H1299 cells. Apoptosis is 
one of the most common cell death mechanisms. Our study showed that dimeric β-carboline (25) 
significantly induced apoptosis in H1299 cells more efficiently than its monomer. This observation 
correlated with the increase in levels of caspase-dependent apoptosis markers and the 
proapoptotic protein, PUMA. These data support our hypothesis that dimeric β-carboline (25) 
induces cell death through caspase-dependent apoptosis mediated by PUMA. 
 
H1299 cells treated with dimeric β-carboline (25) showed a dose-dependent increase in 
PUMA mRNA levels. Although PUMA expression is usually regulated by p53, a transcription factor 
that is not present in H1299, it is also be controlled by other transcription factors such as p73 and 
E2F1.35 However, western blot analysis showed no alteration of these proteins, compared to the 
DMSO control (data not shown).  Our data support a mechanism whereby dimeric β-carboline (25) 
may indirectly modulate PUMA expression and thus contribute to cell death.32 
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The subcellular co-localization analysis demonstrated that both dimeric (25) and 
monomeric (34) β-carbolines predominantly localized in lysosomes.  This action is similar to many 
weakly basic agents such as chloroquine, Lys0516 and manzamine A25, which were reported to 
target lysosomes causing lysosomal dysfunction and consequently autophagy inhibition.  H1299 
cells treated with dimeric- β-carboline (25) showed a dose-dependent increase in LC3II levels, 
indicating increased autophagosome accumulation. Many studies have shown that autophagy and 
apoptosis regulate each other.30, 31, 36 In particular, autophagy was reported to regulate apoptosis 
via modulation of constitutive PUMA expression, which controls the rate of mitochondrial outer 
membrane permeabilization (MOMP).32 These findings support the hypothesis that dimeric β-
carboline (25) accumulates in lysosomes and inhibits autophagy, thereby inducing PUMA 
expression and caspase-dependent apoptosis.  
 
 
 
 
Figure 1.9 Proposed mechanism. 
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1.6. Conclusions 
Inspired by the unique structure and interesting biological activities of neo-kauluamine, we have 
prepared simple dimeric β-carbolines that are significantly more active in both antimicrobial and 
anticancer activities than the corresponding monomeric ligands.  Our results are consistent with 
the importance of multivalency in biological systems. In particular, dimeric β-carboline (25) has 
been shown to be a potential lead compound for the treatment of NSCLC. Our mechanistic studies 
suggest that dimeric β-carboline (25) targets lysosomes in H1299 cells and mediates caspase-
dependent apoptosis through a PUMA induction process. However, the detailed mechanism still 
remains to be established.  
 
1.7. General method and experimental procedures  
1.7.1. General information 
Unless otherwise stated, all reagents were purchased from Sigma Aldrich, Alfa Aesar, 
Acros Organic or TCI America and used without further purification. Manzamine A and 
neokauluamine were kindly provided by Professor Hamann at the University of Mississippi. 1H and 
13C NMR spectra were recorded on Bruker AVII500B (500 MHz) and DRX-500 (500 MHz) 
spectrometers. Chemical shifts are reported relative to the solvent resonance peak δ 7.26 (CDCl3) 
for 1H NMR and δ 77.16 (CDCl3) for 13C NMR. Infrared spectra were recorded on a NaCl plate 
using a Perkin-Elmer 1600 series Fourier transform spectrometer. High-resolution mass spectra 
were obtained by Dr. Rakesh Kohli at the University of Pennsylvania Mass Spectrometry Service 
Center. 
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1.7.2. Synthesis of 9H-pyrido [3,4-b]indole-1-carbaldehyde (29) 
 
9H-pyrido [3,4-b]indole-1-carbaldehyde (29) was prepared by following the previously 
reported procedure with some modification.17 Tryptophan (1g, 6.24 mmol, 1 eq.) in CH2Cl2 (20 mL) 
was added to dimethoxyglyoxal (60% solution in water) (1.13 mL, 7.49 mmol, 1.2 eq.) and TFA (1 
mL). The mixture was stirred at 25oC for 16 h, then poured into 10% NaHCO3 (20 mL). The reaction 
mixture was extracted three times with CH2Cl2 (5 mL). The combined organic layer was washed 
with brine, dried over Na2SO4 and concentrated under reduced pressure to yield 1.5 g of dark brown 
oil.  The crude product was oxidized using KMnO4 (2.96 g, 18.72 mmol, 3 eq.) in THF (70 mL) at 
25oC for 20 h, and then filtered through a thin pad of Celite, washed with THF (50 mL) and EtOAc 
(20 mL). The organic solvent was removed under reduced pressure and the crude product was 
purified by flash column chromatography on silica gel (30% ethyl acetate/hexane) and gave the 
corresponding acetal as yellow oil (1.1 g). The acetal was heated with a mixture of acetic acid:water 
(2:3) at 70°C for 1 h. The reaction was cooled down to 25oC and the solvent was then removed 
under reduced pressure. The residue was treated with 10% NaHCO3 (50 mL) then extracted three 
times with ethyl acetate (15 mL).The crude product was purified by flash column chromatography 
on silica gel (30% EtOAc/Hexane) and gave the desired aldehyde (587.7 mg, 2.99 mmol, 48% 
overall yield) as yellow solid. 1H- and 13C NMR were identical to those previously reported.17 
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1.7.3. General procedure for the synthesis of dimeric- and monomeric- β- carboline analogs.  
 
 
 
A mixture of 9H-pyrido [3,4-b]indole-1-carbaldehyde (60) (1 eq.) and  diamine (61)(0.45 
eq.) in a mixed solvent (CH3OH:CH2Cl2 (2:1)) (0.1M) was stirred at 25oC for 16 h. The solvent was 
evaporated under reduced pressure to give the crude Schiff base, which was used directly in the 
next step without further purification. The solution of the crude product in anhydrous CH3OH (0.1 
M) was added NaBH3CN (10 eq.) at 0°C. The mixture was stirred at 25oC for 16h and then 
concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (15 mL) and washed 
three times with sat. Na2CO3 (aq.) (5 mL). The organic layer was dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by flash chromatography on 
silica gel (NH4OH:CH3OH:CH2Cl2, 1:10:90) to give the corresponding dimeric (62) and monomeric 
β- carbolines (63). 
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1.7.4. Characterization data for dimeric- and monomeric β-carboline analogs 
 
N1-((9H-pyrido[3,4-b]indol-1-yl)methyl)-N2-(2-(((9H-pyrido[3,4-b]indol-1-yl)methyl)amino) 
ethyl)-N2-methylethane-1,2-diamine (25) 
 
 
 
1H NMR (500 MHz, Chloroform-d) δ 10.63 (s,2H), 8.28 (d, J = 5.2 Hz, 2H), 8.06 (d, J = 7.9 Hz, 2H), 
7.79 (d, J = 5.3 Hz, 2H), 7.52 – 7.39 (m, 4H), 7.22 (t, J = 7.4 Hz, 2H), 4.33 (s, 4H), 2.85 (t, J = 5.7 
Hz, 4H), 2.59 (t, J = 5.7 Hz, 4H), 2.25 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 143.37, 140.49, 
137.89, 135.04, 129.05, 128.25, 121.73, 121.51, 119.67, 113.83, 111.81, 56.57, 54.28, 46.72, 
42.63. FTIR (CHCl3 film): 3062.41, 2847.38, 1625.7, 1430.92, 1323.89 cm-1. HRMS: [M-H]- calc. 
476.2563, found 476.2565.  
 
2,2'-oxybis(N-((9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine) (26) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.44 (s, 2H), 8.33 (d, J = 5.3 Hz, 2H), 8.08 (dt, J = 7.9, 1.0 
Hz, 2H), 7.82 (d, J = 5.3 Hz, 2H), 7.46 (dddd, J = 14.8, 8.2, 7.0, 1.1 Hz, 4H), 7.22 (ddd, J = 8.0, 
6.8, 1.3 Hz, 2H), 4.39 (s, 4H), 3.54 (t, J = 5.2 Hz, 4H), 2.85 (t, J = 5.2 Hz, 4H). 13C NMR (126 MHz, 
Chloroform-d) δ 143.38, 140.34, 137.96, 135.02, 129.03, 128.25, 121.71, 121.44, 119.69, 113.76, 
111.74, 70.21, 54.51, 48.88. FTIR (CHCl3 film): 3223.43, 2892.7, 1626.66, 1431.89, 1324.86, 
1123.33 cm-1. HRMS: [M+H]+ calc. 465.2403, found 465.2393.  
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2,2'-(ethane-1,2-diylbis(oxy))bis(N-((9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine) (27) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.26 (s, 2H), 8.29 (d, J = 5.3 Hz, 2H), 8.08 (d, J = 7.9 Hz, 
2H), 7.80 (d, J = 5.2 Hz, 2H), 7.49 (dd, J = 6.2, 1.4 Hz, 4H), 7.23 (ddd, J = 8.0, 6.0, 2.1 Hz, 2H), 
4.35 (s, 4H), 3.66 (t, J = 4.9 Hz, 4H), 2.87 (t, J = 4.9 Hz, 4H), 2.60 (m, 4H). 13C NMR (126 MHz, 
Chloroform-d) δ 143.59, 138.10, 135.10, 129.00, 128.19, 121.77, 121.55, 119.68, 113.69, 111.85, 
70.45, 54.90, 48.86, 46.40. FTIR (CHCl3 film): 3151.11, 2886.91, 1625.7, 1430.92, 1240.97, 1124.3 
cm-1. HRMS: [M+H]+ calc. 509.2665, found 509.2662. [M+Na]+ calc. 531.2484, found, 531.2483.  
 
1,4-bis(4-((9H-pyrido[3,4-b]indol-1-yl)methyl)piperazin-1-yl)benzene (28) 
 
1H NMR (500 MHz, Chloroform-d) δ 9.94 (s, 2H), 8.37 (d, J = 5.3 Hz, 2H), 8.14 (d, J = 7.8 Hz, 2H), 
7.89 (d, J = 5.3 Hz, 2H), 7.58 – 7.50 (m, 4H), 7.29 (ddd, J = 8.0, 6.6, 1.4 Hz, 2H), 6.93 (s, 4H), 4.21 
(s, 4H), 3.21 (t, J = 4.9 Hz, 8H), 2.80 (t, J = 4.8 Hz, 8H). 13C NMR (126 MHz, Chloroform-d) δ 
145.37, 140.06, 138.53, 134.93, 129.05, 128.47, 121.89, 121.65, 120.01, 117.80, 114.01, 111.84, 
64.52, 53.74, 50.64. FTIR (CHCl3 film): 3626.48, 3355.53, 2814.6, 1626.66, 1514.81, 1428.99 cm-
1. HRMS: [M+H]+ calc. 607.3298, found 607.3302.  
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N1-((9H-pyrido[3,4-b]indol-1-yl)methyl)-N2-(2-aminoethyl)-N2-methylethane-1,2-diamine (34) 
 
1H NMR (500 MHz, Chloroform-d) δ 8.16 (dd, J = 5.3, 1.1 Hz, 1H), 8.01 (d, J = 7.9 Hz, 1H), 7.81 
(d, J = 5.3 Hz, 1H), 7.53 – 7.41 (m, 2H), 7.16 (t, J = 7.4 Hz, 1H), 4.21 (s, 2H), 2.74 (t, J = 5.8 Hz, 
2H), 2.65 (t, J = 5.7 Hz, 2H), 2.44 (q, J = 5.5 Hz, 4H), 2.11 – 2.03 (m, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 140.60, 137.90, 135.22, 129.00, 128.19, 121.77, 121.54, 119.55, 113.77, 111.85, 
56.94, 54.52, 46.64, 42.52, 39.48. FTIR (CHCl3 film): 3061.52, 2857.39, 1624.7, 1321.54 cm-1. 
HRMS: [M+H]+ calc. 298.2032, found 298.2035.  
 
 
N-((9H-pyrido[3,4-b]indol-1-yl)methyl)-2-(2-aminoethoxy)ethan-1-amine (35) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.54 (s, 1H), 8.32 (d, J = 5.3 Hz, 1H), 8.10 (d, J = 7.9 Hz, 
1H), 7.84 (d, J = 5.3 Hz, 1H), 7.56 – 7.47 (m, 2H), 7.27 – 7.21 (m, 1H), 4.41 (s, 2H), 3.58 (d, J = 
4.5 Hz, 2H), 3.48 (t, J = 5.2 Hz, 2H), 2.87 (dt, J = 7.0, 4.9 Hz, 4H). 13C NMR (126 MHz, Chloroform-
d) δ 143.44, 140.43, 138.02, 135.09, 129.03, 128.25, 121.73, 121.48, 119.67, 113.74, 111.85, 
72.76, 70.17, 54.58, 48.93, 41.69. FTIR (CHCl3 film): 3158.83, 1626.66, 1567.84, 1324.86, 1121.4 
cm-1. HRMS: [M+H]+ calc. 285.1715, found 285.1714.  
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N-((9H-pyrido[3,4-b]indol-1-yl)methyl)-2-(2-(2-aminoethoxy)ethoxy)ethan-1-amine (36) 
 
 
 
1H NMR (500 MHz, Chloroform-d) δ 10.50 (s, 1H), 8.32 (d, J = 5.3 Hz, 1H), 8.11 (d, J = 7.9 Hz, 
1H), 7.85 (d, J = 5.2 Hz, 1H), 7.56 – 7.49 (m, 2H), 7.27 – 7.21 (m, 1H), 4.42 (s, 2H), 3.70 – 3.61 
(m, 6H), 3.51 (t, J = 5.2 Hz, 2H), 2.91 (t, J = 6.2, 4.9 Hz, 2H), 2.84 (t, J = 5.2 Hz, 2H). 13C NMR 
(126 MHz, Chloroform-d) δ 143.68, 140.46, 138.07, 135.13, 128.99, 128.16, 121.73, 121.54, 
119.63, 113.68, 111.90, 73.29, 70.64, 70.39, 70.35, 54.79, 48.87, 41.73. FTIR (CHCl3 film): 2919.7, 
1625.7, 1566.88, 1455.99, 1122.37 cm-1. HRMS: [M+H]+ calc. 329.1978, found 329.1981. [M-H]- 
calc. 327.1821, found 327.1824. [M+Na]+ calc. 351.1797, found 351.1786. 
 
2,2'-oxybis(N-((7-bromo-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine) (44) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.65 (s, 2H), 8.30 (d, J = 5.3 Hz, 2H), 7.84 (d, J = 8.3 Hz, 
2H), 7.73 (d, J = 5.3 Hz, 2H), 7.51 (d, J = 1.6 Hz, 2H), 7.28 (dd, J = 8.4, 1.6 Hz, 2H), 4.36 (s, 4H), 
3.52 (t, J = 4.9 Hz, 4H), 2.84 (t, J = 4.9 Hz, 4H). 13C NMR (126 MHz, Chloroform-d) δ 143.31, 
141.03, 138.39, 135.02, 128.55, 123.02, 122.79, 121.91, 120.30, 114.76, 113.71, 70.09, 54.04, 
48.90. FTIR (CHCl3 film): 2854.13, 1622.8, 1568.81, 1420.32, 1317.14 cm-1. HRMS: [M+H]+ calc. 
621.0613, found 621.0608. 
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2-(2-aminoethoxy)-N-((7-bromo-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine (45) 
 
1H NMR (500 MHz, Chloroform-d) δ 8.31 (d, J = 5.3 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 
5.3 Hz, 1H), 7.73 (d, J = 1.7 Hz, 1H), 7.32 (dd, J = 8.4, 1.7 Hz, 1H), 4.40 (s, 2H), 3.52 (t, J = 4.6, 
2.9 Hz, 2H), 3.46 (dd, J = 6.2, 3.8 Hz, 2H), 2.88 – 2.80 (m, 4H). 13C NMR (126 MHz, Chloroform-
d) δ 143.17, 141.37, 138.39, 135.05, 128.59, 123.05, 122.78, 121.98, 120.33, 115.10, 113.75, 
71.29, 69.84, 53.37, 48.70, 41.06. FTIR (CHCl3 film): 2856.06, 1621.84, 1567.84, 1420.32, 1319.07 
cm-1. HRMS: [M+H]+ calc. 363.0820, found 363.0819. 
 
2,2'-oxybis(N-((8-bromo-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine) (46) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.33 (s, 2H), 8.34 (d, J = 5.3 Hz, 2H), 8.10 (dd, J = 7.9, 1.0 
Hz, 2H), 7.85 (d, J = 5.3 Hz, 2H), 7.54 – 7.45 (m, 4H), 7.26 – 7.22 (m, 2H), 4.43 (s, 4H), 3.58 (t, J 
= 4.9 Hz, 4H), 2.88 (t, J = 4.9 Hz, 4H). 13C NMR (126 MHz, Chloroform-d) δ 143.42, 140.29, 138.13, 
135.09, 129.06, 128.33, 121.80, 121.50, 119.78, 113.82, 111.80, 70.26, 54.85, 48.96. FTIR (CHCl3 
film): 3062.41, 1625.7, 1565.92, 1430.92 cm-1. HRMS: [M+H]+ calc. 621.0613, found 621.0612. 
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2-(2-aminoethoxy)-N-((8-bromo-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine (47) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.84 (s, 1H), 8.32 (d, J = 5.3 Hz, 1H), 8.10 (dt, J = 7.9, 1.0 
Hz, 1H), 7.85 (d, J = 5.3 Hz, 1H), 7.60 (dt, J = 8.2, 0.9 Hz, 1H), 7.51 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 
7.26 – 7.22 (m, 1H), 4.44 (s, 2H), 3.52 (t, J = 4.8 Hz, 2H), 3.45 (t, J = 5.0 Hz, 2H), 2.84 (dt, J = 11.7, 
5.0 Hz, 4H). 13C NMR (126 MHz, Chloroform-d) δ 142.72, 140.66, 137.98, 135.03, 129.17, 128.40, 
121.69, 121.42, 119.75, 113.95, 112.17, 71.44, 69.76, 53.57, 48.71, 41.16. FTIR (CHCl3 film): 
3369.03, 2917.77, 1627.63, 1563.99, 1430.92 cm-1. HRMS: [M+H]+ calc. 363.0820, found 
363.0819. 
 
2,2'-oxybis(N-((6-methoxy-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine) (48) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 11.29 (s, 2H), 8.30 (d, J = 5.3 Hz, 2H), 7.80 (d, J = 5.2 Hz, 
2H), 7.51 – 7.44 (m, 4H), 7.13 (dd, J = 8.8, 2.5 Hz, 2H), 4.36 (s, 4H), 3.90 (d, J = 1.5 Hz, 6H), 3.16 
(t, J = 4.6 Hz, 4H), 2.56 (t, J = 4.7 Hz, 4H). 13C NMR (126 MHz, Chloroform-d) δ 154.07, 141.72, 
137.20, 135.95, 135.65, 129.12, 121.55, 118.72, 114.20, 113.15, 103.36, 68.82, 56.08, 52.19, 
48.42. FTIR (CHCl3 film): 3136.65, 1567.84, 1496.49, 1290.14, 1214.93 cm-1. HRMS: [M-H]- calc. 
523.2458, found 523.2449. 
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2-(2-aminoethoxy)-N-((6-methoxy-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine (49) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.90 (s, 1H), 8.26 (d, J = 5.2 Hz, 1H), 7.77 (d, J = 5.4 Hz, 
1H), 7.49 (dd, J = 5.7, 3.1 Hz, 2H), 7.14 (dd, J = 8.9, 2.5 Hz, 1H), 4.37 (s, 2H), 3.89 (s, 3H), 3.44 
(dd, J = 6.5, 3.2 Hz, 2H), 3.38 (t, J = 5.0 Hz, 2H), 2.82 – 2.72 (m, 4H). 13C NMR (126 MHz, 
Chloroform-d) δ 154.04, 143.12, 137.39, 135.80, 135.62, 128.92, 121.69, 118.54, 113.85, 113.10, 
103.42, 71.18, 69.83, 56.16, 53.39, 48.79, 41.02. FTIR (CHCl3 film): 2939.95, 1566.88, 1496.49, 
1290.14, 1214.93 cm-1. HRMS: [M+H]+ calc. 315.1821, found 315.1815. 
 
2,2'-oxybis(N-((8-methoxy-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine) (50) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 10.25 (s, 2H), 8.28 (d, J = 5.3 Hz, 2H), 7.76 (d, J = 5.3 Hz, 
2H), 7.63 (dd, J = 7.9, 0.9 Hz, 2H), 7.12 (t, J = 7.9 Hz, 2H), 6.89 (dd, J = 7.9, 0.8 Hz, 2H), 4.41 (s, 
4H), 3.93 (s, 6H), 3.63 (t, J = 4.4 Hz, 4H), 2.89 (t, J = 5.0 Hz, 4H). 13C NMR (126 MHz, Chloroform-
d) δ 146.33, 143.76, 137.94, 134.66, 130.77, 129.10, 122.46, 120.10, 113.94, 113.81, 107.56, 
70.26, 55.55, 54.67, 48.78. FTIR (CHCl3 film): 3065.3, 2836.77, 1631.48, 1578.45, 1480.1, 
1428.99, 1260.25 cm-1. HRMS: [M+H]+ calc. 525.2614, found 525.2611. 
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2-(2-aminoethoxy)-N-((8-methoxy-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine (51) 
 
1H NMR (500 MHz, Chloroform-d) δ 8.28 (dd, J = 5.3, 1.3 Hz, 1H), 7.78 (d, J = 5.1 Hz, 1H), 7.65 
(dd, J = 8.1, 2.1 Hz, 1H), 7.15 (tt, J = 7.8, 1.6 Hz, 1H), 6.93 (d, J = 7.7 Hz, 1H), 4.47 (s, 2H), 3.97 
(d, J = 1.3 Hz, 3H), 3.59 (t, J = 4.7 Hz, 2H), 3.55 (t, J = 4.9 Hz, 2H), 2.95 (t, J = 5.0 Hz, 2H), 2.87 
(t, J = 4.7 Hz, 2H). 13C NMR (126 MHz, Chloroform-d) δ 142.83, 137.84, 120.25, 114.16, 113.83, 
107.82, 70.77, 69.80, 55.71, 48.32, 40.99, 32.75. FTIR (CHCl3 film): 2933.2, 1577.49, 1508.06, 
1428.99, 1326.79, 1261.22 cm-1. HRMS: [M+H]+ calc. 315.1821, found 315.1821. 
 
2,2'-oxybis(N-((7-chloro-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine) (52) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.75 (s, 1H), 8.32 (d, J = 5.4 Hz, 1H), 7.94 (d, J = 8.3 Hz, 
1H), 7.76 (d, J = 5.3 Hz, 1H), 7.42 (d, J = 1.8 Hz, 1H), 7.17 (dd, J = 8.4, 1.9 Hz, 1H), 4.38 (s, 2H), 
3.53 – 3.45 (m, 2H), 2.86 – 2.78 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 143.11, 140.85, 
138.46, 135.29, 134.03, 128.62, 122.58, 120.49, 120.00, 113.77, 111.84, 69.90, 53.97, 48.83. FTIR 
(CHCl3 film): 3142.44, 1625.7, 1425.14 cm-1. HRMS: [M-H]- calc. 531.1467, found 531.1418. 
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2,2'-oxybis(N-((8-chloro-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine) (53) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.47 (s, 2H), 8.31 (d, J = 5.3 Hz, 2H), 7.93 (d, J = 7.8 Hz, 
2H), 7.75 (d, J = 5.3 Hz, 2H), 7.47 (d, J = 7.6 Hz, 2H), 7.15 (t, J = 7.8 Hz, 2H), 4.44 (s, 4H), 3.66 (t, 
J = 4.9 Hz, 4H), 2.91 (t, J = 5.0 Hz, 4H). 13C NMR (126 MHz, Chloroform-d) δ 143.76, 138.69, 
137.54, 134.82, 129.23, 127.41, 123.01, 120.42, 120.13, 117.21, 113.95, 70.34, 54.71, 48.96. FTIR 
(CHCl3 film): 2861.84, 1625.7, 1566.88, 1427.07, 1304.61 cm-1. HRMS: [M+H]+ calc. 533.1623, 
found 533.1632. 
 
2-(2-aminoethoxy)-N-((8-chloro-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine (54) 
 
1H NMR (500 MHz, Chloroform-d) δ 8.33 (d, J = 5.3 Hz, 1H), 7.96 (dd, J = 7.8, 1.0 Hz, 1H), 7.78 
(d, J = 5.3 Hz, 1H), 7.49 (dd, J = 7.8, 0.9 Hz, 1H), 7.16 (t, J = 7.8 Hz, 1H), 4.44 (s, 2H), 3.62 (dd, J 
= 5.5, 4.5 Hz, 2H), 3.49 (t, J = 5.2 Hz, 2H), 2.87 (t, J = 5.1 Hz, 4H). 13C NMR (126 MHz, Chloroform-
d) δ 144.29, 138.79, 137.57, 134.90, 129.19, 127.42, 123.10, 120.43, 120.25, 117.20, 113.95, 
73.22, 70.44, 55.03, 49.04, 41.86. FTIR (CHCl3 film): 2871.49, 1625.7, 1558.2, 1496.49, 1428.99, 
1317.14 cm-1. HRMS: [M+H]+ calc. 319.1326, found 319.1319. 
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2,2'-oxybis(N-((5-chloro-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine) (55) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.70 (s, 2H), 8.35 (d, J = 5.4 Hz, 2H), 8.25 (d, J = 5.4 Hz, 
2H), 7.38 – 7.28 (m, 4H), 7.18 (dd, J = 7.5, 1.0 Hz, 2H), 4.39 (s, 4H), 3.53 (t, J = 4.9 Hz, 4H), 2.84 
(t, J = 4.8 Hz, 4H). 13C NMR (126 MHz, Chloroform-d) δ 143.09, 141.24, 138.35, 134.90, 130.02, 
128.51, 127.97, 120.38, 119.15, 116.00, 110.12, 70.10, 54.44, 48.88. FTIR (CHCl3 film): 2866.67, 
1620.88, 1560.13, 1420.32 cm-1. HRMS: [M-H]- calc. 531.1467, found 531.1476. 
 
2-(2-aminoethoxy)-N-((5-chloro-9H-pyrido[3,4-b]indol-1-yl)methyl)ethan-1-amine (56) 
 
1H NMR (500 MHz, Chloroform-d) δ 10.83 (s, 1H), 8.36 (d, J = 5.4 Hz, 1H), 8.28 (d, J = 5.4 Hz, 
1H), 7.47 – 7.37 (m, 2H), 7.21 (dd, J = 7.2, 1.2 Hz, 1H), 4.42 (s, 2H), 3.58 (dd, J = 5.5, 4.3 Hz, 2H), 
3.51 – 3.44 (m, 2H), 2.87 (td, J = 5.2, 2.3 Hz, 4H). 13C NMR (126 MHz, Chloroform-d) δ 143.41, 
141.35, 138.42, 134.97, 130.00, 128.46, 127.91, 120.29, 119.20, 115.89, 110.28, 72.79, 70.12, 
54.62, 48.92, 41.70. FTIR (CHCl3 film): 2869.56, 1620.88, 1563.99, 1421.28, 1321 cm-1. HRMS: 
[M-H]- calc. 317.1169, found 317.1158. 
 
1.7.5. Biological evaluations 
Cell culture: H1299 cells were cultured and maintained in DMEM medium with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin.  A549, H441, H1373, H1993 and H2009 were kindly 
provided by Professor Lewis Cantley’s lab, Weill Cornell Medical College, Cornell University. These 
cell lines were maintained in PRMI medium with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. All cell lines were maintained in standard tissue culture incubators at 37°C 
and 5% CO2. 
38 
 
 
Cell viability assay: For cell viability assays, Cells were plated in 96-well plates (5000cells/well) 
in triplicate and cultured overnight before treating with compound 25, 34 or manzamine A for 48h. 
Cells were then incubated with Alamar blue (Life Technologies, DAL1025) for 2 h at 37 ̊C and 
viability was read out according to manufacturer’s protocol on a SynergyHT plate reader (BioTek), 
Fluorescence intensity was determined at ex/em: 545/600.  Percent viability was calculated and 
normalized to a no treatment control.  Data analysis (including logarithmic transformation, graphical 
analysis, and IC50 calculation) was conducted using Prism (GraphPad) software. 
 
Western blot analysis: For western blot analysis, cells were treated with indicated compounds at 
indicated concentrations for 24h and lysed in RIPA buffer containing protease/phosphatase 
inhibitors. 50 µg of protein lysate was loaded in each lane andseparated by Novex™ 10% Tris-
Glycine Mini Denaturing Protein Gel (Invitrogen) using MES buffer. Proteins were next transferred 
onto a polyvinylidene fluoride (PVDF) membrane (Millipore, USA) and blocked in 5% milk made in 
in TBS-Tween buffer for 1h at 25oC. Membranes were next incubated with the indicated primary 
antibodies at 4°C overnight. Membranes were then washed sequentially three times (10 mins 
interval) with TBS-Tween buffer before incubating with the corresponding HRP secondary 
antibodies at 25oC for 1h. After, secondary antibody incubation, membranes were then washed 
again three times with TBS-Tween buffer before analyzing using chemiluminescence with ECL. 
 
LC3 immunofluorescence analysis: H1299 were transfected with GFP-LC3 using 
Lipofectamine® 3000 Reagent (Invitrogen) according to the manufacturer’s protocol and incubated 
at 37oC for 24h. The medium was replaced before treatments with DMSO, compound 34 (20 µM), 
compound 25 (3, 5 and 10 µM) or manzamine A (10 µM) for 24h. Cells were then washed with 
PBS, fixed with freshly prepared 4% paraformaldehyde in PBS buffer for 10 min at 37°C and 
mounted onto slides in medium containing DAPI (Prolong Gold Antifade, Molecular Probes, 
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Eugene) and analyzed by confocal microscopy. Thirty cells per treatment were scored for GFP-
puncta using ImageJ software. 
 
Quantitative real-time PCR: H1299 cells were treated with DMSO, compound 25 and 34 at the 
indicated concentrations for 24 h. Cells were lysed using QIAshredder columns.  Total RNA was 
isolated using RNeasy Mini Kit (Qiagen) and on-column DNase digestions (Qiagen) following the 
manufacturer’s protocol.  Equal amounts of RNA from these samples were then used to make 
cDNA using a High Capacity Reverse Transcription Kit (Applied Biosciences, 4368814).  
Quantitative PCR (qPCR) was performed using Brilliant III UltraFast SYBR Green QPCR Mix kits 
(Agilent Technologies) on a Stratagene Mx3005P device (Agilent Technologies).  Data analysis of 
fold changes in gene transcription levels was done using the MxPro program (Stratagene).  RNA 
expression levels were normalized to the housekeeping gene 18S.  Primer sequences used are 
human PUMA; Forward: 5’-ACCTCAACGCACAGTACGAG-3’, Reverse: 5’-
CCCATGATGAGATTGTACAGGA-3’.  
 
Confocal microscopy: H1299 cells were plated on Poly-L-Lysine-coated slips and cultured for 
24h, then treated with DMSO, compound 25 or compound 34 at the indicated concentrations. After 
24 h, cells were washed in PBS and fixed with 4% paraformaldehyde in PBS at room temperature 
for 15 min, followed by permeabilization in 0.25% Triton-X-100 for 15 mins. Cells were next blocked 
with 10% normal goat serum (NGS) for 1h. The cells then were incubated with a rabbit polyclonal 
antibody against cleaved caspase 3 for 2h at room temperature. The cover slips then were washed 
three times with PBS before incubation with a secondary antibody using the same procedure as for 
the primary antibody. The cover slips were then mounted on slides with mounting media 
(VECTASHIELD Antifade Mounting Medium, Vector Labolatories) and were examined with 
confocal microscopy. 
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Guava Nexin Assay: H1299 cells were treated with DMSO, compound 25 or compound 34 at the 
indicated concentrations for 48h and performed the assay according to the manufacture’s protocol. 
 
Live image analysis: H1299 cells were treated with DMSO and the ß-carboline compounds for for 
1h. The culture medium was removed. The cells were stained with MitoTracker® Green FM 
(Invitrogen) and LysoTracker® Red DND-99 (Invitrogen) according to the manufacture’s protocol 
and analyzed using confocal microscope. 
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CHAPTER 2. MODEL STUDY FOR THE DIMERIZATION OF MANZAMINE A TOWARD 
NEOKAULUAMINE 
 
2.1. Introduction 
Neokauluamine is a marine ß-carboline alkaloid isolated from an Indo-Pacific sponge 
(family Petrosiidae, order Haplosclerida) in 2001 by Hamann et.al.10 Its complex structure was 
elucidated as a dimeric form of manzamine A, the first isolated manzamine alkaloid.6 
Neokauluamine exhibited interesting antimalarial and anticancer activities. However, because of 
the limited supply (Table 2.1) and the complex structure of neokauluamine, its stereochemistry was 
not completely assigned and its biological activity was not widely studied. Manzamine A is more 
relatively abundant in Nature compared to other manzamine alkaloids. We therefore elected to 
study the use of manzamine A as a starting material for the total synthesis of neokauluamine. 
 
2.2. Total synthesis and structural modification of manzamine A 
Manzamine A was isolated from an Okinawa sponge in 1986 by Higa et.al. as a 
hydrochloric salt.6 Its X-ray crystal structure (Figure 2.1) showed that it possessed a ß-carboline 
moiety attached to the pentacyclic core comprising two six-membered rings, as well as 5-, 13- and 
8- membered rings. The total synthesis and structural modifications of manzamine A have been 
reported and provide precedent for the synthetic methods that could be employed for the 
dimerization of manzamine A to neokauluamine. 
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The lipophilic extract contents from Indo-Pacific sponge (family Petrosiidae, order 
Haplosclerida).10 
Manzamine A    0.66% 
Manzamine E    0.003% 
Manzamine J    0.0017% 
Ircinal A    0.008% 
6-deoxymanzamine X   0.0021% 
ent-8-hydroxymanzamine A  1.24% 
ent-manzamine F   0.055% 
neokauluamine    0.0048% 
 
Table 2.1 Relative natural abundance of neokauluamine compared to other manzamine alkaloids. 
 
 
 
Figure2. 1 X-ray crystal structure of manzamine A hydrochloride. 
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2.2.1. Total synthesis of manzamine A 
Manzamine A has attracted much interest as a complex target for total synthesis. 7,8,9Since 
the first total synthesis by our group9 in 1998 until now, multiple synthetic approaches toward 
manzamine A have been reported. The following are highlights for the successfully enantioselective 
total synthesis of manzamine A. 
 
The first total synthesis of manzamine A was reported by our group in 1998, shown in 
Scheme 2.1.9 The key step involved a stereoselective intramolecular photoaddition of the 
vinylogous amide 64, followed by retro-Mannich fragmentation and Mannich ring closure, 
respectively, to form the tetracyclic system (labeled in red) in 69. Steps were then performed to 
complete the synthesis of manzamine A in 31 total steps. 
 
 
 
Scheme 2. 1 Key steps for the first total synthesis of manzamine A reported by Winkler et.al. 
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In 2002, Martin et.al. (Scheme 2.2) reported a stereoselective total synthesis of 
manzamine A (23 steps).37 The tricyclic ring system in 72 was constructed via the intramolecular 
Diels-Alder reaction of the vinylogous amide 71. Two ring closing metathesis were later used to 
form the 13-membered ring in 75 and the 8-membered ring in 77, respectively. 
 
Scheme 2. 2 Key steps for the total synthesis of manzamine A by Martin et.al. 
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Fukuyama et.al. reported the synthesis of manzamine A (29 steps) involving the highly 
strained 15-membered ring precursor 78.7 [3, 3]-sigmatropic rearrangement of the allyl cyanate 79 
was performed to stereoselectively introduce the nitrogen functionality at the sterically hindered C-
34 position in 80. Similarly to Martin’s approach, the 8-membered ring in 82 was formed by ring 
closing metathesis of the diene 81. 
 
Scheme 2. 3 Key steps for the total synthesis of manzamine A by Fukuyama et.al. 
 
Recently, Dixon et.al. reported the shortest (18 steps) stereoselective synthesis of 
manzamine A.38 Michael addition of the lactam 84 into the nitro alkene 83 yielded 85 as a major 
diastereomer. Nitro-Mannich/lactonization reaction of the nitro alkane 85, the amine 86 and 
formaldehyde gave the lactam 87. Another intramolecular nitro-Mannich reaction was performed to 
transform the lactam 88 to the desired ring system in 89. 
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Scheme 2. 4 Key steps for the total synthesis of manzamine A by Dixon et.al. 
 
2.2.2. Structural modification of manzamine A 
To study structure-activity relationship (SAR) of manzamine A, derivatives of manzamine 
A were prepared and evaluated for biological activities. For example, the importance of the 
pentacyclic ring system in manzamine A for antibacterial and antiprotozoal properties was 
determined by the analog 90, 91 and 92 (Scheme 2.5),39 prepared by ring opening metathesis of 
manzamine A with ethylene. The hydrochloric acid salt of manzamine A was treated with the 
second generation Grubbs catalyst under ethylene atmosphere to afford a mixture of 90 and 92 
(4:1) in 73% yield.  No formation of 91 was observed under these conditions.  This result suggested 
that the alkene in the D ring is more reactive than the one in the E ring, a result that could be 
attributed to steric hindrance. However the analog 91 could be selectively prepared as shown in 
Scheme 2.6. Selective dihydroxylation of the D ring and subsequently acylation led to the protected 
diol compound 93. Ring-opening metathesis of the azocine ring was then performed to yield 94 in 
90% yield. The transformation of the diacetate back to the desired alkene in 91 was successfully 
done via Corey–Winter olefin synthesis.40 
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Scheme 2. 5 Ring-opening metathesis of manzamine A for the study of the importance of its 
pentacyclic system to antibacterial and antiprotozoal properties. 
 
Scheme 2. 6 Regioselective ring-opening of the azocine ring of manzamine A. 
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2.3. Synthetic analysis for the conversion of manzamine A toward neokauluamine. 
Neokauluamine was first isolated in 2001 by Hamann et.al.41 Its 1H- and 13C-NMR spectra 
showed two set of nonidentical peaks that closely correlated to those of manzamine A (1-25C and 
1’-25’C). Besides other extensive NMR experiments, the key HMBC and NOESY correlations of 
the molecule suggested the structure shown in Figure 2.2. However, since NOE correlation 
between 26’-H and 31’-H was not observed, the stereochemistries of C-30’-, C-31’- and C-34’ were 
not assigned. 
 
Figure2. 2 Key HMBC (blue) and NOESY (red) correlations of neokauluamine reported by Hamann 
et.al. 
Recently, Tsukamoto et.al discovered a novel manzamine alkaloid called pre-
neokauluamine (Scheme 2.7) and found that pre-neokauluamine converts to the structure of  the 
dimeric structure of neokauluamine upon storage at -20oC for two months.13 This observation 
clearly indicated that the units A and B in neokauluamine were derived from the same molecule 
(pre-neokauluamine) and revealed the missing stereochemistries at 30’-, 31’- and 34’-C. The 
dimerization mechanism was proposed to occur through the ring-opening of pre-neokauluamine to 
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form the corresponding reactive iminium diol which then underwent reaction as shown in Scheme 
2.7. 
 
 
Scheme 2. 7 Proposed mechanism for the dimerization of pre-neokauluamine toward 
neokauluamine. 
To convert manzamine A to neokauluamine, we envisioned a three step pathway (Scheme 
2.8): 1) isomerization of the alkene functionality from the 32,33 alkene in manzamine A to the 30,31 
alkene in 94 2) dihydroxylation of the 30,31 alkene to form the diol 95 and selective C-H activation 
at C-34 to form the requisite iminium in 93; followed by 3) “double” nucleophilic attack of the 
appropriate hydroxyl group to the iminium to form the desired dimeric structure neokauluamine. 
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Scheme 2. 8 Key steps for the dimerization of manzamine A toward neokauluamine.  
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2.4. Model study for the key dimerization step  
The key dimerization step proposed by Tsukamoto et.al. is shown in Scheme 2.9.  Since 
the dimerization reaction involves only rings C and E, we planned to study the dimerization using 
the partial structure labeled in red in Scheme 2.9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. 9 Model system for the study of the dimerization step.  
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Although the structure of neokauluamine was fully assigned from the observation that it is 
a dimer of pre-neokauluamine by Tsukamoto et.al. , the dimerization of the model system 94 could 
theoretically yield eight different isomers, as shown in Scheme 2.10. Isomers 95 and 97 are 
homodimers from the linkages at the C-31-C-31’ hydroxyls and the C-30-C-30’ hydroxyls, as 
labeled in Scheme 2.10, respectively. Isomers 96 are heterodimers from the aminal formation of 
the C-30’- C-31 or the C-30- C-31’hydroxyls. There are three stereoisomers for each of 95 and 97 
and four stereoisomers for 96. Among them, only isomers 95-C, 96, 97-C are not symmetrical. We 
used Gaussian with B3LYP/6-31G(d) to perform geometry optimization calculation for each of 
these possible isomers. Interestingly, the lowest energy isomer is 96-A which does not correspond 
to the reported structure of neokauluamine. These results add further significance to the proposed 
model studies, which could lead to the stereochemistry of the natural product or, alternatively, to 
the lowest-energy structure based on these calculations. 
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Scheme 2. 10 Possible isomers from the dimerization of the model system 94 and relative energy 
of the possible dimers from geometry optimization calculation using Gaussian with B3LYP/6-
31G(d)  . 
54 
 
In previous work from our laboratory, Dr. Matilda Bingham had discovered that compound 
98 could be selectively oxidized at C-34 by RuO2.xH2O/ NaOCl to form a mixture of transannular 
cyclization products 99 and 100 after acid-catalyzed acetal deprotection (Scheme 2.11), of which 
100 shares the ring system of pre-neokauluamine. However, no dimerization was observed from 
either 99 or 100, a result that we attributed to the attenuated electron-density of the aminal nitrogen, 
which could impede the ring-opening that is required for the key dimerization step. We reasoned 
that reduction of lactam 98 to the corresponding tertiary amine would promote the requisite ring-
opening of the hemiaminal.  
 
 
 Scheme 2. 11 Previous effort to study the dimerization of the model system 94. 
 
Our initial efforts to make the amine version of 98 was to prepare compound 107, shown 
in Scheme 2.12.  We reasoned that compound 107 could be dihydroxylated and oxidized to form 
the desired aminals 108 and 109. Starting from the commercially available (S)-1-Boc-2-
formylpyrrolidine 101, compound 107 was prepared in 5 steps involving Wittig and SN2 reactions. 
Unfortunately, compound 107 was found to be difficult to handle because of its volatility, 
hydrophilicity and high polarity.  
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Scheme 2. 12 Initial effort to prepare model system 94. 
  
We envisioned that selective reduction of the lactam in compound 99 and 100 could yield 
the designed models 108 and 109. The model molecule 98 prepared by Bingham was a mixture of 
diastereomers. To simplify the characterization in later steps, we therefore revised the synthetic 
route for the preparation of the enantiopure version of 98, lactam 114.  Shown in Scheme2.13, SN2 
reaction of the known lactam 11042 and the alkyl bromide 111 yielded the diene 112. Ring-closing 
metathesis and Pd-catalyzed hydrogenation of compound 113 gave the enantiopure compound 
114 in good yield.  The oxidation of 114 by the same reaction condition gave similar result to what 
observed by Bingham. The successfully selective reduction of the lactams 115 and 116 in the 
presence of hemiaminals was performed by conversion of the lactams to thioamides and 
subsequently reduction with Raney nickel, yielding the pre-neokauluamine-like compounds 123 
and 124. 
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To study the dimerization of pre-neokauluamine, we treated a mixture of 123 and 124 with 
catalytic amount of different kinds of acids (TFA, TsOH and PPTS) in various solvents (CH2Cl2, 
CHCl3, THF and toluene) to initiate the iminium formation. We observed no reaction when the 
dimerization was performed at 25oC using the acids and solvents listed above. However, when a 
mixture of 123 and 124 was treated with a catalytic amount of TFA in toluene and warmed up to 
50oC (Scheme 2.14), we observed 100% conversion from the pre-neokauluamine-like compounds 
123 and 124  to a compound that has 32 and 20 different protons and carbons, respectively, as 
determined by 1H-and 13C NMR spectroscopy. This result strongly suggests the formation of the 
asymmetric isomers 95-C, 96, 97-C  (Scheme 2.10). The structure of the resulting dimer was 
further explored by COSY, HSQC and HMBC experiments that allowed us to assign its proton and 
carbon peaks and indicated the heterodimer 96. Shown in Table 2.2, the 13C peak for C-34 is more 
downfield compared to the one for C-34’. This is opposite to what observed for neokauluamine. 
NOE experiments on the dimeric product gave correlations of H31-H31’ and H26-26’,  which are 
consistent with the dimeric structure  96-A, for which the indicated distances are all within 5 Å, 
according to the structures optimized by the geometry optimization on WebMO computational 
server, as shown in Table 2.3. These NMR data and the relatively lowest energy isomer of 96-A 
(Scheme 2.10) are all consistent with our conclusion that the model dimer that we have prepared 
has the structure shown in 96-A. However, X-ray analysis of a crystalline derivative will be needed 
to unambiguously confirm the proposed structure. 
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Scheme 2. 13 Stereoselective synthesis of the model system for the study of the dimerization of 
pre-neokauluamine.  
 
Scheme 2. 14 Model study for the dimerization of the pre-neokauluamine like compounds 123 
and 124.  
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Table 2.2 1H- and 13C NMR data (ppm, CDCl3, 500 MHz) for neokauluamine and dimer 96.   
 
neokauluamine 
Hemisphere A 13C 1H Hemisphere B 13C 1H 
26 75.5 3.85 26' 75.9 3.66 
28 47.2 3.15 28' 44.6 3.57, 3.18 
30 72.2 3.76 30' 72.7 4.14 
31 84.4 4.41 31' 67.2 3.69 
34 89.7 - 34' 104.5 - 
Dimer 96 
Hemisphere A 13C 1H Hemisphere B 13C 1H 
26 56.8 3.55, 2.38 26' 54 3.42, 2.57 
28 45.5 3.08, 2.88 28' 43.6 3.35, 2.51 
30 70.1 3.39 30' 71.9 3.84 
31 86.2 4.27 31' 65.7 3.28 
34 108.3 - 34' 95.5 - 
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Table 2.3 Calculated distances in space between H-atoms in isomer 96. 
 
2.5. Model study of the oxidation key step  
Since compound 107 (Scheme 2.12) was found to be difficult to handle, to study the 
selective C-H activation at C-34 as opposed to C-26 or C-28 (Scheme 2.15), we planned to use 
the model system 125 in Scheme 2.15. The free hydroxyl group could allow us to put on 
functionalities that make the compound non-volatile, less polar and UV active. The synthesis of the 
125 (a model system for 95) is shown in Scheme 2.16. The alkene 133 could be prepared from the 
known enantiopure alkene 12843 in 5 steps involving SN2 and ring closing metathesis reactions. 
The dihydroxylation of the alkene 133 with OsO4 gave 134 as a pure diastereomer, similar to the 
product obtained by the Sharpless reagent, AD-mix-β. Protection of the resulting diol with 2, 2-
dimethoxypropane gave the model system 125 which was ready for the study of the selective 
oxidation at C-34. 
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Scheme 2. 15 Model system for the study of the key oxidation step. 
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Scheme 2. 16 Synthesis of the model system 125. 
 
C-H activation of tertiary amines has been studied and utilized in natural product 
synthesis.18,44–47 The reaction usually proceeds through oxidation of the tertiary nitrogen to form N-
oxide (136) or ammonium radical (139) and subsequent α-H abstraction to form reactive iminium 
species (140), shown in Scheme 2.17.48 Selectivity for the α-H abstraction depends on 
thermodynamic, kinetic and stereoelectronic effects. In his synthesis of aspidophytine, Corey et.al. 
performed oxidative lactonization using potassium ferricyanide to selectively form the aminolactone 
143 in excellent yield.18 Szántay et.al. reported iodine-aided epimerization of vinca alkaloid 145 via 
the hemiaminal 146 (Scheme 2.18).49 However, only recovered starting material was observed 
when 125 was subjected to these reaction conditions. 
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Scheme 2. 17 Proposed mechanism for C-H activation of tertiary amine 135 by a) Polonovski-
Potier Reaction and by b) one-electron oxidation of tertiary amine 135. 
 
Scheme 2. 18 Examples of selective oxidation of tertiary amines in natural product synthesis. 
We further investigated the oxidation of the model compound 125 and found that by treating 
with mCPBA in CH2Cl2 at 0oC, the tertiary amine was quantitatively converted to the corresponding 
N-oxide (148) in 1 hour. We therefore performed Polonovski-Potier reaction by treating the N-oxide 
(148) with trifluoroacetic anhydride to form the corresponding reactive iminium ions which were 
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then trapped with cyanide ions (Scheme2.19).47 Unfortunately, we observed only 149 and 150 as 
major and minor products, respectively with no desired isomer 151. Working with Dr. Simon Berritt 
at UPenn Parallel Reaction Screening Service Center, we screened for the conditions that would 
yield the desired product by variations of solvents (dioxane, acetonitrile, dichloromethane, 
methanol, toluene and tetrahydrofuran) and anhydrides (Ac2O, Ms2O, Tf2O, TFAA). Unfortunately, 
none of them was promising.  
  
 
Scheme 2. 19 Polonovski-Potier reaction of model 125.  
(Note: * configuration not determined)  
 
Selective oxidation at C-34 was attempted by first introducing a double bond at 32,33 in 
159. In this case, the C-34 position is made allylic and therefore expected to be more susceptible 
to oxidation. The model compound 159 was prepared as outlined in Scheme 2.20. Following a 
known procedure,50 the hemiaminal 152 was stereoselectively attacked by the vinyl cuprate, 
yielding the alkene 153. Ester reduction of 153 with LiAlH4, subsequent protection of the resulting 
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alcohol and Boc-deprotection led to the amine 155. Alkylation of the amine 155 with tosylate 156 
yielded the diene 157 which was then underwent ring-closing metathesis to afford the model 
compound 159. Unfortunately, 159 treated with the same Polonovski-Potier reaction condition led 
to an inseparable mixture (Scheme 2.21). After hydrogenation, we observed the oxidation at C-26 
(160) as the product, similar to the selectivity observed previously for the oxidation of model 125 
(Scheme 2.19).  
 
 
Scheme 2. 20 Synthesis of model system 159. 
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Scheme 2. 21 Polonovski-Potier reaction of model 159. 
(Note: * configuration not determined) 
 
2.6. Conclusions  
The dimerization of manzamine A toward neokauluamine involves three key steps: 1) 
double bond isomerization from 32,33 to 30,31, 2) C-34 selective oxidation to pre-neokauluamine,  
and 3) selective C-31-C-30’ hydroxyl dimerization, respectively. We studied the key dimerization 
step from the pre-neokauluamine-like structures, 123 and 124, and found that they were selectively 
dimerized to a single hetero dimer after being warmed up to 50oC with catalytic TFA in toluene. Our 
extensive NMR experiments and computational data suggest that the resulting dimer is the isomer 
96-A. However, X-ray crystal analysis is needed to confirm the structure. Since 96-A does not 
correspond to the structure present in the reported structure of neokauluamine, we reason that the 
other functionalities in the structure of pre-neokauluamine, e.g. the macrocyclic 13-membered ring, 
crucially affect the stereoselectivity of the dimerization step. A model study for the key oxidation 
step was also performed. Unfortunately, the Polonovski reaction of both the saturated (125) and 
unsaturated (159) model systems led to C-26 oxidation as the major product with no observation 
of the desired oxidation product 151. Further investigation to alter the selectivity for the oxidation 
at 34-C is therefore necessary. 
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2.7. General method and experimental procedures  
2.7.1. General information 
Unless otherwise stated, all reagents were purchased from Sigma Aldrich, Alfa Aesar, 
Acros Organic or TCI America and used without further purification.1H and 13C NMR spectra were 
recorded on Bruker AVII500B (500 MHz) and DRX-500 (500 MHz) spectrometers. Chemical shifts 
are reported relative to the solvent resonance peak δ 7.26 (CDCl3) for 1H NMR and δ 77.16 (CDCl3) 
for 13C NMR. Infrared spectra were recorded on a NaCl plate using a Perkin-Elmer 1600 series 
Fourier transform spectrometer. High-resolution mass spectra were obtained by Dr. Rakesh Kohli 
at the University of Pennsylvania Mass Spectrometry Service Center. 
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2.6.2. Procedure for the synthesis of model system 123 and 124 
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(S)-1-(2-((4S,5R)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl)ethyl)-5-vinylpyrrolidin-2-one (112) 
 
NaH (0.043 g, 1.08 mmol, 1 eq.) was added to a solution of 110 (prepared in 5 steps42 from 
L-pyroglutamic acid) (0.12 g, 1.08 mmol, 1 eq.) in DMF (1 mL). The suspension was stirred at 25oC 
for 1h under argon atmosphere. A solution of 11151 (0.3 g, 1.276 mmol, 1.2 eq.) in DMF (1 mL) was 
then added and the reaction mixture was stirred at 25oC for 16h. H2O (5mL) was then added. The 
mixture was extracted with EtOAc (5mL) three times. The combined organic layer was washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by 
silica gel chromatography (gradient 1-50% EtOAc/Hexane) to yield 112 as a colorless oil (0.12 g, 
42% yield). 1H NMR (500 MHz, Chloroform-d) δ 5.63 (dddd, J = 17.7, 10.1, 7.5, 1.8 Hz, 1H), 5.52 
(dddd, J = 16.9, 10.1, 8.3, 1.8 Hz, 1H), 5.22 – 5.01 (m, 4H), 4.36 (t, J = 6.9 Hz, 1H), 4.03 – 3.95 
(m, 1H), 3.90 (dddd, J = 13.7, 7.7, 6.2, 1.8 Hz, 1H), 3.45 – 3.36 (m, 1H), 2.94 – 2.85 (m, 1H), 2.31 
– 2.02 (m, 3H), 1.60 (dddd, J = 12.5, 9.4, 6.2, 1.8 Hz, 1H), 1.49 (dddd, J = 11.7, 9.8, 5.6, 2.6 Hz, 
1H), 1.39 (ddddd, J = 13.3, 9.5, 5.6, 3.8, 1.8 Hz, 1H), 1.31 (d, J = 1.7 Hz, 3H), 1.19 (d, J = 1.8 Hz, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 174.58, 137.65, 133.76, 118.18, 117.74, 108.10, 79.22, 
76.07, 61.23, 38.06, 29.79, 28.35, 28.03, 25.43. FTIR (CHCl3 film): 2984.3, 2935.13, 1689.34, 
1419.35, 1216.86 cm-1. HRMS: [M+H]+ calc. 266.1756, found 266.1757. 
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 (3aS,9aS,11aR,Z)-2,2-dimethyl-4,5,8,9,9a,11a-hexahydro-[1,3]dioxolo[4,5-e]pyrrolo[1,2-
a]azocin-7(3aH)-one (113) 
 
A solution of 112 (0.07 g, 0.26 mmol, 1 eq.) in CH2Cl2 (50 mL) was degassed before adding 
Grubbs’ cat. (2nd gen) (0.022 g, 0.026 mmol, 0.1 eq.). The mixture was stirred for 24 h under argon 
atmosphere and concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (gradient 20-80% EtOAc/Hexane) to yield 113 as a colorless oil (0.046g, 75% 
yield). 1H NMR (500 MHz, Chloroform-d) δ 5.70 – 5.64 (m, 2H), 5.16 (dd, J = 6.5, 3.1 Hz, 1H), 4.43 
(dd, J = 15.0, 8.9 Hz, 1H), 4.31 (ddd, J = 10.3, 6.3, 3.6 Hz, 1H), 4.06 – 3.97 (m, 1H), 2.73 (dd, J = 
15.0, 9.9 Hz, 1H), 2.51 (dt, J = 16.4, 9.5 Hz, 1H), 2.33 – 2.07 (m, 3H), 1.90 – 1.76 (m, 2H), 1.47 (s, 
3H), 1.37 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 173.97, 135.87, 130.91, 108.76, 81.49, 
75.51, 55.66, 39.10, 29.39, 29.18, 27.79, 26.06, 25.58. FTIR (CHCl3 film): 2983.34, 1681.62, 
1423.21, 1379.82, 1248.68, 1062.59 cm-1. HRMS: [M+H]+ calc. 238.1443, found 238.1446. 
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(3aS,9aR,11aR)-2,2-dimethyloctahydro-[1,3]dioxolo[4,5-e]pyrrolo[1,2-a]azocin-7(3aH)-one (114) 
 
Pd/C (0.002 g, 0.0169 mmol, 0.1 eq.) was added to a solution of 113 (0.04 g, 0.169 mmol, 
1 eq.) in EtOAc (5 mL). The suspension was charged with a H2 balloon and stirred at 25oCfor 16h. 
The reaction mixture was then filtered through a thin pad of Celite to yield 114 as a colorless film 
(0.032 g, 80% yield). 1H NMR (500 MHz, Chloroform-d) δ 4.22 (dt, J = 11.1, 5.1 Hz, 1H), 4.15 – 
4.07 (m, 2H), 3.62 (tdd, J = 7.1, 5.0, 3.4 Hz, 1H), 2.46 – 2.35 (m, 2H), 2.29 (dt, J = 17.1, 9.1 Hz, 
1H), 2.04 (dddd, J = 13.5, 11.6, 5.6, 3.5 Hz, 1H), 1.97 – 1.82 (m, 2H), 1.80 – 1.69 (m, 2H), 1.61 – 
1.46 (m, 3H), 1.36 (s, 3H), 1.29 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 175.86, 107.61, 80.09, 
58.35, 39.17, 32.52, 30.48, 28.35, 26.11, 25.81, 24.92, 20.17. FTIR (CHCl3 film): 2930.31, 1680.66, 
1420.32, 1046.19 cm-1. HRMS: [M+H]+ calc. 240.1600, found 240.1593. 
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(7S,8R,10aR)-8-hydroxyoctahydro-3H-7,10a-epoxypyrrolo[1,2-a]azocin-3-one (115) and 
(7S,8R,10aR)-7-hydroxyoctahydro-3H-8,10a-epoxypyrrolo[1,2-a]azocin-3-one (116) 
 
 
RuO4.H2O (0.005 g, 0.038 mmol, cat.) was added into a solution of 114 (0.2 g, 0.84 mmol, 
1eq.) in EtOAc (3 mL) at 0oC under argon. 5%NaClO (aq) (1.68 ml) was added in 3 portions over 
3 h. The reaction was kept at 0oC until 114 was completely consumed (monitored by LCMS). 
Isopropanol (1.5 mL) was then added. The mixture was extracted three time with EtOAc (10 mL). 
The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure. The residue was then brought up into MeOH (1 mL). TsOH (0.01 g) was added 
and the mixture was stirred at 25oC for 16h. The mixture was concentrated under reduced pressure 
and purified by silica gel chromatography (2-5 % MeOH/CH2Cl2) to yield a mixture of the two 
isomers (115:116 = 10:2) (0.067g, 41% yield). 1H NMR (500 MHz, Chloroform-d) δ 4.49 (dt, J = 
9.4, 2.2 Hz, 0.2H), 4.15 – 4.06 (m, 1.8H), 3.83 (td, J = 5.3, 4.7, 2.6 Hz,0.2H), 3.78 (dt, J = 4.7, 2.3 
Hz, 1H), 3.76 – 3.70 (m, 0.2H), 3.50 – 3.40 (m, 1H), 3.18 (ddd, J = 14.7, 8.6, 2.4 Hz, 0.2H), 2.55 – 
2.10 (m, 7H), 2.06 (ddd, J = 13.6, 10.2, 6.7 Hz, 1H), 1.99 – 1.91 (m, 1.8H), 1.86 – 1.75 (m, 1.5H), 
1.55 (dd, J = 14.3, 5.5 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 174.15, 173.59, 101.67, 88.00, 
84.65, 74.59, 66.93, 36.61, 35.85, 35.20, 33.42, 32.07, 31.87, 30.72, 30.25, 28.85, 28.27, 28.00, 
23.72. FTIR (CHCl3 film): 3335.28, 2947.66, 1669.09, 1368.25, 1175.4, 1029.8 cm-1. HRMS: 
[M+Na]+ calc. 220.0950, found 220.0955. 
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 (7S,8R,10aR)-8-((tert-butyldiphenylsilyl)oxy)octahydro-3H-7,10a-epoxypyrrolo[1,2-a]azocin-3-
one (117) and (7S,8R,10aR)-7-((tert-butyldiphenylsilyl)oxy)octahydro-3H-8,10a-epoxypyrrolo[1,2-
a]azocin-3-one (118) 
 
Imidazole (0.06 g, 0.9 mmol, 1.5 eq.) and TBDPSCl (0.247 g, 0.9 mmol, 1.5 eq.) were 
added to a mixture of 115 and 116 (0.12g, 0.6 mmol, 1 eq.) in CH2Cl2 (3 mL). The mixture was 
stirred at 25oC for 16 h. The solvent was then removed under reduced pressure. The residue was 
purified by silica gel chromatography (20 % EtOAc/Hexane) to yield a mixture of the two isomers 
(117:118 = 10:2) (0.26g, 98% yield). Compound 117: 1H NMR (500 MHz, Chloroform-d) δ 7.67 
(ddq, J = 9.3, 7.9, 1.5 Hz, 4H), 7.46 – 7.35 (m, 6H), 4.00 (dd, J = 14.1, 7.9 Hz, 2H), 3.76 (dq, J = 
3.5, 1.7 Hz, 1H), 3.36 – 3.26 (m, 1H), 2.50 – 2.28 (m, 3H), 2.15 – 1.91 (m, 4H), 1.84 (dd, J = 15.2, 
6.1 Hz, 1H), 1.73 (dd, J = 13.6, 5.5 Hz, 1H), 1.28 – 1.16 (m, 1H), 1.09 (d, J = 1.2 Hz, 9H). 13C NMR 
(126 MHz, Chloroform-d) δ 174.08, 135.86, 133.98, 129.94, 127.83, 87.97, 68.28, 36.15, 33.77, 
31.21, 29.00, 28.51, 27.09, 23.75, 19.42. Compound 118: 1H NMR (500 MHz, Chloroform-d) δ 
7.72 – 7.59 (m, 4H), 7.46 – 7.33 (m, 6H), 4.44 – 4.36 (m, 1H), 3.91 – 3.80 (m, 1H), 3.80 – 3.72 (m, 
1H), 2.94 – 2.84 (m, 1H), 2.57 (ddd, J = 16.8, 9.8, 5.7 Hz, 1H), 2.40 (ddd, J = 16.5, 9.5, 6.3 Hz, 
1H), 2.32 (ddd, J = 13.4, 9.8, 6.2 Hz, 1H), 2.13 (ddd, J = 13.4, 9.5, 5.7 Hz, 1H), 2.06 – 1.94 (m, 
3H), 1.83 (td, J = 7.0, 3.2 Hz, 2H), 1.54 – 1.44 (m, 1H), 1.06 (s, 9H). 13C NMR (126 MHz, Chloroform-
d) δ 173.48, 135.95, 134.08, 133.83, 129.94, 127.83, 101.60, 85.60, 36.30, 35.13, 33.21, 31.63, 
30.33, 28.90, 27.09, 19.30. FTIR (CHCl3 film): 2931.27, 1698.02, 1407.78, 1111.76 cm-1. HRMS: 
[M+Na]+ calc. 458.2127, found 458.2131. 
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(7S,8R,10aR)-8-((tert-butyldiphenylsilyl)oxy)octahydro-3H-7,10a-epoxypyrrolo[1,2-a]azocine-3-
thione (119) and (7S,8R,10aR)-7-((tert-butyldiphenylsilyl)oxy)octahydro-3H-8,10a-
epoxypyrrolo[1,2-a]azocine-3-thione (120) 
 
 
A mixture of 117 and 118 (0.18 g, 0.4 mmol, 1 eq.) and Lawesson’s reagent (0.184 g, 0.45 mmol, 
1.1 eq.) in toluene (2 mL) was heated up to 70oC for 1h. The mixture was then cooled down to 25oC 
and absorbed on silica gel for silica gel chromatography (dry load). The eluent was 3-5% 
EtOAc/Hexane to obtain 119 (0.126 g, 70% yield) and 10-20% EtOAc/Hexane to obtain 120 (0.036 
g, 20% yield). Compound 119: 1H NMR (500 MHz, Chloroform-d) δ 7.67 (ddt, J = 13.0, 6.6, 1.4 
Hz, 4H), 7.46 – 7.33 (m, 6H), 4.56 (dd, J = 14.9, 8.4 Hz, 1H), 4.07 – 4.00 (m, 1H), 3.81 (dt, J = 3.8, 
2.1 Hz, 1H), 3.46 (tdd, J = 12.5, 6.4, 2.3 Hz, 1H), 3.08 – 2.96 (m, 1H), 2.85 (dtd, J = 18.3, 9.3, 2.3 
Hz, 1H), 2.35 (td, J = 13.5, 6.3 Hz, 1H), 2.17 – 2.11 (m, 2H), 2.11 – 2.04 (m, 1H), 1.95 (dddd, J = 
14.7, 13.2, 5.5, 3.7 Hz, 1H), 1.85 (ddt, J = 12.9, 6.3, 2.1 Hz, 1H), 1.78 (ddd, J = 13.6, 5.5, 2.0 Hz, 
1H), 1.45 – 1.36 (m, 1H), 1.10 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 199.26, 135.69, 133.58, 
129.91, 127.75, 94.47, 73.72, 67.82, 41.41, 40.58, 35.87, 29.60, 27.82, 26.95, 23.20, 19.27. 
Compound 120: 1H NMR (500 MHz, Chloroform-d) δ 7.75 – 7.60 (m, 4H), 7.48 – 7.34 (m, 6H), 
4.38 (d, J = 8.8 Hz, 1H), 4.19 – 4.08 (m, 1H), 3.94 – 3.86 (m, 1H), 3.85 – 3.73 (m, 1H), 3.12 (ddd, 
J = 17.7, 9.3, 2.6 Hz, 1H), 2.95 (dt, J = 17.6, 8.8 Hz, 1H), 2.38 (dt, J = 12.8, 9.3 Hz, 1H), 2.21 – 
2.08 (m, 3H), 2.06 – 1.98 (m, 1H), 1.84 (dt, J = 6.8, 4.0 Hz, 2H), 1.56 – 1.48 (m, 1H), 1.07 (s, 9H). 
13C NMR (126 MHz, Chloroform-d) δ 198.96, 135.99, 133.54, 129.97, 127.86, 107.69, 85.28, 75.61, 
42.66, 40.46, 36.74, 34.98, 29.79, 27.64, 27.10, 19.38. FTIR (CHCl3 film): 2952.48, 1463.71, 
1426.1, 1110.8, 1029.8 cm-1. HRMS: [M+H]+ calc. 452.2080, found 452.2083. 
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(7S,8R,10aS)-8-((tert-butyldiphenylsilyl)oxy)octahydro-1H-7,10a-epoxypyrrolo[1,2-a]azocine 
(121) and (7S,8R,10aS)-7-((tert-butyldiphenylsilyl)oxy)octahydro-1H-8,10a-epoxypyrrolo[1,2-
a]azocine (122) 
 
 
Raney Nickel (activated in H2O) (0.9 g) was washed two times with H2O (1 mL) and EtOH 
(1mL) before suspending in EtOH (5 mL). The suspension was then added to a solution of 119 and 
120 (0.12 g, 0.266 mmol, 1 eq.) in EtOH (5 mL). The mixture was stirred under argon for 30 min at 
25oC before being filtered through a thin pad of Celite (washed with MeOH (20 mL)) to afford a 
mixture of 121 and 122 in (0.069 g, 62% yield). 1H NMR (500 MHz, Chloroform-d) δ 7.69 (td, J = 
6.7, 3.3 Hz, 4H), 7.44 – 7.34 (m, 6H), 4.01 – 3.93 (m, 1H), 3.72 (td, J = 3.7, 1.7 Hz, 1H), 3.44 (d, J 
= 2.1 Hz, 1H), 3.33 (ddd, J = 13.6, 11.4, 5.1 Hz, 1H), 3.17 (q, J = 8.3 Hz, 1H), 2.94 (td, J = 8.4, 2.6 
Hz, 1H), 2.73 (ddd, J = 14.1, 6.6, 3.1 Hz, 1H), 2.29 (td, J = 12.6, 6.0 Hz, 1H), 2.21 – 2.06 (m, 2H), 
1.95 (qd, J = 8.0, 4.8 Hz, 1H), 1.89 – 1.70 (m, 3H), 1.56 (ddd, J = 13.4, 5.4, 3.6 Hz, 1H), 1.09 (d, J 
= 2.6 Hz, 9H), 0.90 – 0.81 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 136.03, 134.42, 129.69, 
127.63, 89.51, 74.11, 69.50, 52.60, 41.93, 40.48, 29.49, 27.46, 27.06, 20.82, 20.57, 19.35. FTIR 
(CHCl3 film): 2931.27, 2856.06, 1698.02, 1427.07, 1110.8 cm-1. HRMS: [M+H]+ calc. 422.2515, 
found 422.2519. 
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 (7S,8R,10aS)-octahydro-1H-7,10a-epoxypyrrolo[1,2-a]azocin-8-ol (123) and (7S,8R,10aS)-
octahydro-1H-8,10a-epoxypyrrolo[1,2-a]azocin-7-ol (124) 
 
A solution of 121 and 122 (0.05 g, 0.119 mmol, 1eq.) and pyridine (150 µL) in THF (300 
µL) was cooled down to 0oC. HF.Py (70%HF) (150 µL) was then added and the reaction was stirred 
at 25oC for 16h. Sat. NaHCO3 (5mL) was then added. The mixture was extracted with 
25%isopropanol/CHCl3 (5 mL) three times. The combined organic layer was washed with brine (2 
mL) and concentrated under reduced pressure to afford a mixture of 123 and 124 (0.018 g, 
87%yield). 1H NMR (500 MHz, Chloroform-d) δ 4.02 (d, J = 7.3 Hz, 1H), 3.73 – 3.62 (m, 1H), 3.58 
– 3.48 (m, 1H), 3.21 (h, J = 7.4, 6.7 Hz, 1H), 2.94 (t, J = 8.6 Hz, 1H), 2.87 – 2.74 (m, 1H), 2.36 (ddt, 
J = 18.1, 14.2, 5.8 Hz, 2H), 2.16 (dq, J = 13.7, 6.8 Hz, 1H), 2.13 – 2.00 (m, 1H), 1.93 – 1.78 (m, 
2H), 1.81 – 1.68 (m, 2H), 1.72 – 1.58 (m, 1H), 1.24 – 1.12 (m, 1H). 13C NMR (126 MHz, Chloroform-
d) δ 89.59, 73.81, 67.93, 52.59, 41.81, 40.36, 29.01, 27.42, 20.70, 19.99. FTIR (CHCl3 film): 
3303.46, 2959.23, 1258.32 cm-1. HRMS: [M+H]+ calc. 184.1338, found 184.1346. 
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2.6.3. Procedure for acid-catalyzed dimerization of model 123 and 124 
 
A mixture of 123 and 124 (0.01 g, 0.05 mmol, 1 eq.) with catalytic amount of TFA in toluene 
(100 µL) was heated up to 50oC for 16h. The mixture was then cooled down to 25oC and 
concentrated under reduced pressure to afford the product 96 in quantitative yield. 1H NMR (500 
MHz, Chloroform-d) δ 4.28 (ddt, J = 8.8, 4.0, 1.9 Hz, 1H), 3.88 – 3.80 (m, 1H), 3.57 (dt, J = 11.4, 
5.8 Hz, 1H), 3.46 – 3.33 (m, 3H), 3.29 (q, J = 2.8 Hz, 1H), 3.09 (t, J = 12.3 Hz, 1H), 2.93 – 2.82 (m, 
2H), 2.58 (dt, J = 11.3, 7.1 Hz, 1H), 2.51 (ddd, J = 12.5, 9.4, 5.6 Hz, 1H), 2.39 (ddd, J = 11.2, 8.6, 
6.4 Hz, 1H), 2.20 (dddd, J = 15.5, 11.3, 7.4, 3.5 Hz, 1H), 2.12 (ddt, J = 16.4, 11.9, 2.0 Hz, 1H), 2.01 
– 1.62 (m, 14H), 1.63 – 1.54 (m, 1H), 1.52 – 1.45 (m, 1H), 1.40 (ddq, J = 14.8, 9.7, 4.8 Hz, 1H). 13C 
NMR (126 MHz, Chloroform-d) δ 108.24, 95.40, 86.20, 71.93, 70.12, 65.73, 55.78, 53.94, 45.50, 
43.59, 39.02, 37.13, 36.11, 28.20, 25.72, 24.95, 23.51, 22.86, 20.78, 20.16. FTIR (CHCl3 film): 
3388.32, 1425.14, 1200.47, 1129.12 cm-1. HRMS: [M+H]+ calc. 367.2597, found 367.2343. 
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2.6.4. Procedure for the synthesis of model system 125 
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tert-butyl (2S,5S)-2-(but-3-en-1-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)pyrrolidine-1-carboxylate 
(129) 
 
Step1: A solution of 128 (prepared in 3 steps from L-pyroglutamic acid methyl ester43) (0.21 g, 
0.741 mmol, 1 eq.) in THF (15 mL) was cooled to 0oC under argon before adding LiAlH4 (0.042 g, 
1.11 mmol, 1.5 eq.). The mixture was stirred at 0oC for 45 min. An aqueous solution of saturated 
Potassium sodium tartrate (aq) (5 mL) was then added and the mixture was stirred vigorously for 
15 min. The mixture was diluted in EtOAc (20 mL) and the layers were separated. The organic 
layer was wash with brine (10 mL) and concentrated under reduced pressure. The resulting 
colorless oil was used in the next step without further purification. 
Step2: Imidazole (0.1 g, 1.48 mmol, 2 eq.) and TBDPSCl (0.3g, 1.11 mmol, 1.5 eq.) were added to 
a solution of the residue from step 1 in CH2Cl2 (5 mL) at 0oC. The mixture was allowed to warm to 
25oC and stirred at 25oC for 16h. The reaction was then quenched with saturated aqueous NH4Cl 
(5 mL). The layers were separated. The aqueous layer was extracted three times with CH2Cl2 (5 
mL). The combined organic layer was washed with brine (10mL), dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by silica gel chromatography (5% 
EtOAc/Hexane) to yield 129 as a colorless oil (0.296 g, 81% yield). 1H NMR (500 MHz, Chloroform-
d) δ 7.74 – 7.65 (m, 4H), 7.41 (dt, J = 13.5, 7.0 Hz, 7H), 5.89 – 5.72 (m, 1H), 5.13 – 4.87 (m, 2H), 
4.07 – 3.40 (m, 3H), 2.22 – 1.80 (m, 7H), 1.73 – 1.56 (m, J = 6.2, 5.4 Hz, 1H), 1.55 – 1.25 (m, 9H), 
1.16 – 1.04 (m, 10H). 13C NMR (126 MHz, Chloroform-d) δ 154.97, 138.49, 135.65, 133.70, 129.69, 
127.74, 114.48, 79.12, 59.72, 58.53, 34.57, 30.88, 28.57, 26.97, 19.37. FTIR (CHCl3 film): 3071.57, 
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2961.64, 2857.99, 2278.97, 1958.84, 1887.97, 1823.37, 1694.16, 1392.35, 1173.95, 1112.24 cm -
1. HRMS: [M+H]+ calc. 494.3090, found 494.3093. 
 
(2S,5S)-2-(but-3-en-1-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)pyrrolidine (130) 
 
A solution of 129 (0.42 g, 0.85 mmol, 1 eq.), Hunig’s base (0.22 g, 1.7 mmol, 2eq.) in 
CH2Cl2 (6 mL) was cooled to 0oC. TMSOTf (0.27 g, 1.02 mmol, 1.2 eq.) was then added and the 
mixture was stirred at 0oC for 1h. The reaction was then quenched with sat. NaHCO3 (aq) (10 mL). 
The layers were then separated. The aqueous layer was extracted with CH2Cl2 (5 mL) three times. 
The combined organic layers were washed with sat. NH4Cl (aq.) (10 mL) and brine (10 mL), dried 
over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (10% EtOAc/Hexane) to yield 130 as a colorless oil (0.29 g, 87% yield). 1H NMR 
(500 MHz, Chloroform-d) δ 7.75 – 7.63 (m, 4H), 7.48 – 7.33 (m, 6H), 5.84 (ddt, J = 16.8, 10.1, 6.6 
Hz, 1H), 5.04 (dq, J = 17.1, 1.7 Hz, 1H), 4.97 (ddt, J = 10.2, 2.1, 1.3 Hz, 1H), 3.73 (dd, J = 10.1, 
4.8 Hz, 1H), 3.64 (dd, J = 10.2, 5.4 Hz, 1H), 3.28 (tt, J = 7.4, 5.1 Hz, 1H), 3.08 (dq, J = 8.7, 6.7 Hz, 
1H), 2.71 (s, 1H), 2.13 (tddd, J = 8.0, 6.2, 2.9, 1.2 Hz, 1H), 1.89 (dddd, J = 11.9, 8.6, 6.6, 4.8 Hz, 
1H), 1.77 (ddt, J = 12.6, 8.6, 7.4 Hz, 1H), 1.63 (dddd, J = 16.0, 9.9, 7.9, 4.5 Hz, 2H), 1.54 (ddd, J 
= 13.1, 6.6, 2.2 Hz, 1H), 1.39 – 1.27 (m, 1H), 1.08 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 
138.71, 135.80, 133.77, 133.75, 129.85, 127.88, 127.85, 114.75, 66.89, 60.35, 59.37, 35.72, 31.81, 
31.63, 27.55, 27.11, 27.05, 19.49. FTIR (CHCl3 film): 3366.14, 2929.34, 2856.06, 1642.09, 
1427.07, 1111.76 cm-1. HRMS: [M+H]+ calc. 394.2566, found 394.2565. 
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(2S,5S)-1,2-di(but-3-en-1-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)pyrrolidine (132) 
 
A mixture of 130 (0.25 g, 0.635 mmol, 1 eq.), 4-bromo-1-butene (131) (0.129 g, 0.953 
mmol, 1.5 eq.) and K2CO3 (0.263 g, 1.905 mmol, 3 eq.) in DMF (10 mL) was stirred at 25oC for 16h. 
H20 (20 mL) was then added and the mixture was extracted three times with EtOAc (3 x 10mL). 
The combined organic layers were washed two times with H2O (15 mL) and brine (15 mL). The 
crude product was dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by silica gel chromatography (3% EtOAc/Hexane) to yield 132 as a colorless oil (0.14 g, 
50% yield). 1H NMR (500 MHz, Chloroform-d) δ 7.78 – 7.70 (m, 4H), 7.49 – 7.38 (m, 6H), 5.86 (ddt, 
J = 16.9, 10.2, 6.5 Hz, 1H), 5.74 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.10 – 4.91 (m, 2H), 3.64 (dd, J 
= 10.0, 4.8 Hz, 1H), 3.44 (dd, J = 10.0, 8.1 Hz, 1H), 2.90 (tt, J = 8.0, 4.7 Hz, 1H), 2.75 – 2.64 (m, 
2H), 2.64 – 2.56 (m, 1H), 2.18 – 1.97 (m, 4H), 1.91 – 1.75 (m, 3H), 1.75 – 1.64 (m, 1H), 1.46 – 1.36 
(m, 1H), 1.32 (dtd, J = 13.2, 9.5, 5.2 Hz, 1H), 1.12 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 
139.16, 137.12, 137.10, 135.78, 135.75, 134.14, 134.05, 129.65, 127.70, 115.38, 114.22,114.19, 
68.12, 65.57, 64.85, 53.62, 34.82, 32.73, 30.93, 29.79, 27.33, 27.06, 27.03, 19.36. FTIR (CHCl3 
film): 3072.05, 2930.79, 2857.51, 1640.64, 1428.03, 1112.73 cm-1. HRMS: [M+H]+ calc. 448.3036, 
found 448.3034. 
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(3S,10aS,Z)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-1,2,3,5,6,9,10,10a-octahydropyrrolo [1,2-
a]azocine (133) 
 
A solution of 132 (0.03 g, 0.0628 mmol, 1 eq.) in CH2Cl2 (13 mL) was degassed by bubbling 
through argon gas for 30 min before adding TsOH (0.01 g, 0.0628 mmol, 1 eq.). The mixture was 
stirred at 25oC for 30 min before adding Grubbs’ cat (2nd Gen) (0.006 g, 0.0063 mmol, 0.1 eq.). The 
mixture was stirred at 25oC under argon atmosphere for 24h. Sat. NaHCO3 (aq) (5 mL) was then 
added. The mixture was then extracted with CH2Cl2 (5 mL) three times. The combined organic 
layers were then washed with brine (5 mL), dried over Na2SO4 and concentrated under reduced 
pressure. The residue was purified by silica gel chromatography (gradient: 20-100% 
EtOAc/Hexane) to yield 133 as a colorless oil (0.02 g, 79% yield). 1H NMR (500 MHz, Chloroform-
d) δ 7.77 – 7.70 (m, 4H), 7.46 – 7.35 (m, 6H), 5.74 – 5.57 (m, 2H), 3.69 (dd, J = 9.9, 5.1 Hz, 1H), 
3.55 (dd, J = 9.9, 6.1 Hz, 1H), 2.88 (tq, J = 15.3, 5.4, 4.4 Hz, 2H), 2.81 (td, J = 9.1, 5.0 Hz, 1H), 
2.59 (tdd, J = 11.9, 7.8, 5.8 Hz, 1H), 2.41 – 2.25 (m, 2H), 2.09 – 1.97 (m, 1H), 1.94 – 1.80 (m, 3H), 
1.56 – 1.45 (m, 1H), 1.45 – 1.36 (m, 1H), 1.36 – 1.25 (m, 2H), 1.08 (s, 9H). 13C NMR (126 MHz, 
Chloroform-d) δ 135.81, 135.79, 134.15, 130.97, 129.62, 129.53, 127.70, 69.61, 68.73, 63.17, 
55.46, 36.70, 30.61, 29.83, 28.31, 26.97, 23.98, 19.36. FTIR (CHCl3 film): 3012.75, 2929.82, 
2857.02, 1471.9, 1428.03, 1112.73 cm-1. HRMS: [M+H]+ calc. 420.2723, found 420.2728. 
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(3S,10aR)-3-(((tert-butyldiphenylsilyl)oxy)methyl)decahydropyrrolo[1,2-a]azocine-7,8-diol (134) 
 
A solution of 133 (0.03 g, 0.0715 mmol, 1 eq.) in acetone:H20 (4:1)(1mL) was cooled to 
0oC. 2.5% OsO4 in tBuOH (0.002 g, 0.007 mmol, 0.1 eq.) and NMO (0.01 g, 0.079 mmol, 1.1 eq.) 
were added and the mixture was stirred at 0oC under argon atmosphere for 30 min. Solid Na2SO3 
(0.1 g) was then added and the mixture was stirred at 25oC for 10 min. The solvent was removed 
under reduced pressure. The residue was extracted with CH2Cl2 (5 mL) three times. The combined 
organic layers were then washed with brine (5 mL), dried over Na2SO4 and concentrated under 
reduced pressure. The residue was purified by silica gel (gradient 10-80% EtOAc/Hexane) to yield 
134 as a colorless oil (0.02 g, 64% yield). 1H NMR (500 MHz, Chloroform-d) δ 7.68 (ddq, J = 8.1, 
5.9, 2.1 Hz, 4H), 7.46 – 7.34 (m, 6H), 3.93 (d, J = 7.4 Hz, 1H), 3.73 (dd, J = 10.4, 5.5 Hz, 1H), 3.67 
(s, 1H), 3.63 (dd, J = 10.4, 5.8 Hz, 1H), 3.34 (s, 1H), 3.14 (ddd, J = 13.2, 12.0, 3.7 Hz, 1H), 2.91 
(ddt, J = 11.7, 8.8, 2.9 Hz, 1H), 2.79 (dq, J = 9.3, 5.6 Hz, 1H), 2.19 (ddd, J = 12.0, 4.6, 2.7 Hz, 1H), 
2.05 – 1.87 (m, 2H), 1.86 – 1.73 (m, 3H), 1.66 (dddd, J = 12.4, 11.0, 9.4, 6.9 Hz, 1H), 1.55 (dq, J = 
14.2, 3.6 Hz, 1H), 1.47 – 1.34 (m, 2H), 1.07 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 135.70, 
133.53, 133.51, 129.80, 127.81, 70.70, 69.88, 68.60, 66.34, 61.00, 47.85, 32.97, 31.23, 30.68, 
28.08, 27.74, 26.95, 26.92, 19.3. FTIR (CHCl3 film): 3397.96, 3070.12, 3048.91, 2930.31, 2857.02, 
1668.12, 1589.06, 1471.42, 1428.03 cm-1. HRMS: [M+H]+ calc. 454.2777, found 454.2780. 
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(7S,9aR)-7-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyldecahydro-[1,3]dioxolo[4,5-
e]pyrrolo[1,2-a]azocine (125) 
 
A mixture of 134 (0.015 g, 0.033 mmol, 1eq.), 2,2-dimethoxypropane (0.034 g, 0.33 mmol, 
10 eq.) and TsOH (0.006 g, 0.033 mmol, 1 eq.) in CH2Cl2 (1 mL) was stirred at 25oC for 30 min. 
Sat. NaHCO3 (aq) (5 mL) was added. The mixture was extracted with CH2Cl2 (5 mL) three times. 
The combined organic layers were then washed with brine (5 mL), dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by silica gel (5% EtOAc/Hexane) 
to yield 125 as a colorless oil (0.19 g, 79% yield). 1H NMR (500 MHz, Chloroform-d) δ 7.85 – 7.62 
(m, 4H), 7.55 – 7.32 (m, 6H), 4.17 (dd, J = 11.1, 6.0 Hz, 1H), 4.10 (ddd, J = 11.4, 6.0, 2.6 Hz, 1H), 
3.64 (dd, J = 10.1, 5.2 Hz, 1H), 3.54 (dd, J = 10.0, 5.5 Hz, 1H), 2.99 (ddd, J = 12.9, 4.8, 3.0 Hz, 
1H), 2.80 (dq, J = 10.6, 5.2 Hz, 1H), 2.41 – 2.29 (m, 2H), 2.22 (qd, J = 12.9, 3.9 Hz, 1H), 2.04 (dtd, 
J = 14.5, 11.6, 2.9 Hz, 1H), 1.96 – 1.87 (m, 1H), 1.84 (dq, J = 12.1, 6.6, 6.2 Hz, 1H), 1.77 (dq, J = 
13.3, 3.4 Hz, 1H), 1.54 – 1.45 (m, 2H), 1.42 (s, 3H), 1.41 – 1.36 (m, 2H), 1.34 (s, 3H), 1.27 (ddd, J 
= 16.9, 8.4, 3.8 Hz, 1H), 1.07 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 135.75, 135.70, 134.02, 
133.98, 129.66, 127.78, 127.72, 105.73, 80.76, 69.43, 68.29, 63.58, 54.97, 34.66, 34.05, 30.96, 
28.21, 28.03, 26.97, 26.95, 25.27, 24.84, 19.32. FTIR (CHCl3 film): 2931.27, 2857.99, 1651.73, 
1428.03, 1365.35, 1112.73 cm-1. HRMS: [M+H]+ calc. 494.3090, found 494.3107. 
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2.6.5. Procedure for Polonovski-Potier reaction of the model system 125 
 
A solution of 125 (0.05 g, 0.1 mmol, 1eq.) in CH2Cl2 (1 mL) was cooled to 0oC and treated 
with mCPBA (0.021 g, 0.12 mmol, 1.2 eq.) The reaction was stirred at 0oC until the starting material 
was all consumed (monitored by TLC, mobile phase: 20% EtOAc/Hexane, Rf = 0.4). TFAA (0.042 
g, 0.2 mmol. 2eq.) was then added and the reaction was allowed to warm to 25oC and stirred at 
25oC until the preformed N-oxide was all consumed (monitored by LCMS). The solvent and excess 
TFAA were removed under reduced pressure. The residue was dissolved in acetonitrile (1 mL). 
NaCN (0.01 g, 0.15 mmol, 1.5 eq.) was added and the mixture was stirred at 25oC for 16h. To the 
reaction was then added sat. NaHCO3 (aq.) (5 mL) and the aqueous layer was extracted three 
times with EtOAc (5 mL). The combined organic layers were then washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by preparative TLC 
(5% Et2O/Hexane) to yield 149 (0.015 g, 29% yield) and 150 (0.002 g 4% yield).  
Compound 149: 1H NMR (500 MHz, Chloroform-d) δ 7.69 (td, J = 7.6, 1.5 Hz, 4H), 7.49 – 7.32 (m, 
6H), 4.13 (dd, J = 10.9, 6.0 Hz, 1H), 4.08 (ddd, J = 11.4, 6.0, 2.7 Hz, 1H), 3.73 (d, J = 10.0 Hz, 1H), 
3.56 (d, J = 9.9 Hz, 1H), 3.07 (ddd, J = 13.2, 5.1, 2.9 Hz, 1H), 2.65 (t, J = 12.5 Hz, 1H), 2.55 (ddd, 
J = 12.4, 8.2, 4.2 Hz, 1H), 2.33 – 2.18 (m, 2H), 2.00 (dddd, J = 26.3, 14.9, 12.5, 3.3 Hz, 2H), 1.89 
– 1.73 (m, 2H), 1.64 – 1.55 (m, 3H), 1.51 (dd, J = 12.2, 6.2 Hz, 1H), 1.39 (s, 3H), 1.32 (s, 3H), 1.08 
(s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 135.79, 135.77, 134.94, 132.86, 132.74, 130.09, 
128.00, 127.98, 127.86, 119.67, 106.17, 80.14, 77.81, 70.46, 68.93, 63.02, 52.31, 33.73, 33.69, 
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30.60, 28.16, 26.83, 25.27, 24.44, 19.38. FTIR (CHCl3 film): 2932.23, 1428.03, 1112.73, 1046.19 
cm-1. HRMS: [M+H]+ calc. 519.3043, found 519.3040. 
Compound 150: 1H NMR (500 MHz, Chloroform-d) δ 7.67 (ddt, J = 15.6, 6.5, 1.6 Hz, 4H), 7.49 – 
7.36 (m, 6H), 4.48 (dd, J = 11.1, 5.9 Hz, 1H), 4.40 (t, J = 4.0 Hz, 1H), 4.13 (ddd, J = 11.5, 5.9, 2.8 
Hz, 1H), 3.68 (dd, J = 10.3, 3.7 Hz, 1H), 3.59 – 3.49 (m, 1H), 3.19 – 3.08 (m, 1H), 2.84 – 2.73 (m, 
1H), 2.25 (ddd, J = 15.1, 11.3, 3.8 Hz, 1H), 2.03 (dd, J = 17.9, 10.4 Hz, 2H), 1.88 – 1.69 (m, 3H), 
1.47 – 1.41 (m, 3H), 1.41 (s, 3H), 1.33 (s, 3H), 1.26 (s, 1H), 1.04 (s, 9H). 13C NMR (126 MHz, 
Chloroform-d) δ 135.73, 135.70, 133.24, 130.00, 127.96, 118.67, 106.34, 77.75, 76.26, 68.91, 
67.08, 59.92, 54.02, 36.00, 30.99, 30.69, 28.08, 27.00, 26.94, 25.06, 24.71, 19.26. HRMS: [M+H]+ 
calc. 519.3043, found 519.3042. 
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2.6.6. Procedure for the synthesis of model system 159 
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1-(tert-butyl) 2-methyl (2S,5S)-5-vinylpyrrolidine-1,2-dicarboxylate (153) 
 
Under argon atmosphere, 1 M vinyl bromide in THF (36.1 mL, 36.1 mmol, 4 eq.) was added 
to Mgo (turnings) (1.05 g, 43.3 mmol, 4.8 eq.) and small amount of iodine. The mixture was heated 
to reflux for 1h. The resulting vinyl magnesium bromide solution was then cooled to 25oC before 
being transferred to a suspension of CuBr-Me2S (7.1 g, 34.56 mmol, 3.83 eq.) in THF (20 mL) at – 
40oC.  The resulting mixture was stirred for 45 min at – 40oC. The reaction mixture was cooled to -
78oC and BF3-Et2O (4.45 ml, 36.096 mmol, 4 eq.) was added. After 30 min, compound 152 
(prepared in 3 steps from L-pyroglutamic acid methyl ester50) (2.34 g, 9.024 mmol, 1eq.) in THF 
(15 mL) was added and the solution was stirred at -78oC for 2 h and at 25oC for 2 h. The mixture 
of sat. aq. NH4Cl (22 mL) and conc. NH4OH (3 mL) was added and the solution was stirred at 25oC 
for 45 min. The reaction mixture was diluted with EtOAc (100 mL), washed with water (3x30 mL), 
brine (30 mL) and was dried over Na2SO4. After the solvent was evaporated under reduced 
pressure, the residue (3 g) was purified by silica gel chromatography (10% EtOAc/Hexane) to yield 
153 as a colorless oil (1.63 g, 71% yield). 1H NMR (500 MHz, Chloroform-d) δ 5.84 – 5.66 (m, 1H), 
5.15 – 4.98 (m, 2H), 4.50 (dt, J = 59.3, 7.0 Hz, 1H), 4.41 – 4.26 (m, 1H), 3.72 (dd, J = 4.0, 1.8 Hz, 
4H), 2.29 – 2.11 (m, 2H), 1.97 – 1.87 (m, 1H), 1.76 – 1.62 (m, 1H), 1.41 (dd, J = 10.4, 1.7 Hz, 12H). 
13C NMR (126 MHz, Chloroform-d) δ 173.71, 173.38, 154.49, 153.57, 138.48, 137.96, 114.25, 
114.02, 80.14, 80.09, 59.76, 59.59, 59.21, 52.25, 52.09, 30.11, 29.33, 28.44, 28.41, 28.39, 27.43. 
FTIR (CHCl3 film): 2977.55, 1749.12, 1698.02, 1390.42, 1166.72 cm-1. HRMS: [M+Na]+ calc. 
278.1368, found 278.1367. 
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tert-butyl (2S,5S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-5-vinylpyrrolidine-1-carboxylate (154) 
 
Step1: A solution of 153 (0.9 g, 3.525 mmol, 1 eq.) in THF (40 mL) was cooled to 0oC and treated 
with LiAlH4 (0.2 g, 5.29 mmol, 1.5 eq.). The mixture was stirred at 0oC for 1h before adding sat. 
Rochelle salt solution (20 mL). The mixture was allowed to warm to 25oC and stirred vigorously at 
25oC for 30 min. The mixture was then diluted with EtOAc (50mL). The layers were then separated. 
The aqueous layer was extracted with EtOAc (10mL) for three times. The combined organic layer 
was washed with brine (15 mL), dried over Na2SO4 and concentrated under reduced pressure. The 
resulting residue was used in the next step without further purification. 1H NMR (500 MHz, 
Chloroform-d) δ 5.71 (ddd, J = 16.8, 10.8, 6.4 Hz, 1H), 5.11 – 4.93 (m, 2H), 4.45 – 4.19 (m, 2H), 
4.15 – 4.03 (m, 1H), 3.78 – 3.65 (m, 1H), 3.65 – 3.54 (m, 1H), 2.12 – 1.99 (m, 2H), 1.69 – 1.54 (m, 
1H), 1.49 (t, J = 5.2 Hz, 1H), 1.43 (d, J = 9.2 Hz, 9H). 13C NMR (126 MHz, Chloroform-d) δ 156.91, 
138.36, 113.93, 67.99, 60.97, 60.11, 30.2, 28.48, 26.41. 
Step2: The residue from the first step was dissolved in CH2Cl2 (15 mL) and cooled to 0oC. Imidazole 
(0.58 g, 8.6 mmol, 2.5 eq.) and TBDPSCl (1.9 g, 6.86 mmol, 2 eq.) were then added. The reaction 
was allowed to warm to 25oC and stirred at 25oC for 12h. Sat. NH4Cl (aq) solution (10 mL) was 
then added. The mixture was extracted with CH2Cl2 (5 mL) three times. The combined organic layer 
was then washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The 
residue was purified by silica gel chromatography (3% EtOAc/Hexane) to yield 154 as a colorless 
oil (1.6 g, 98% yield). 1H NMR (500 MHz, Chloroform-d) δ 7.72 – 7.59 (m, 4H), 7.48 – 7.33 (m, 6H), 
5.78 (dddd, J = 21.1, 16.7, 10.3, 5.8 Hz, 1H), 5.12 – 4.95 (m, 2H), 4.33 (dt, J = 44.5, 7.0 Hz, 1H), 
4.10 – 3.89 (m, 1H), 3.86 – 3.45 (m, 2H), 2.30 – 1.93 (m, 3H), 1.61 (ddd, J = 17.0, 12.1, 6.1 Hz, 
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1H), 1.38 (d, J = 52.9 Hz, 9H), 1.08 (d, J = 1.7 Hz, 9H). 13C NMR (126 MHz, Chloroform-d) δ 154.28, 
153.76, 139.30, 138.37, 135.69, 135.67, 135.65, 135.62, 134.93, 133.88, 133.80, 133.70, 133.55, 
129.78, 129.64, 127.84, 127.80, 127.74, 127.72, 113.53, 113.35, 64.09, 63.86, 60.27, 59.65, 58.78, 
58.68, 31.71, 30.21, 28.82, 28.54, 28.49, 26.98, 26.69, 25.81, 25.56, 19.41, 19.37. FTIR (CHCl3 
film): 3071.08, 2961.16, 2931.27, 2857.99, 1693.19, 1387.53, 1111.76 cm-1. HRMS: [M+H]+ calc. 
466.2777, found 466.2793. 
 
(2S,5S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-5-vinylpyrrolidine (155) 
 
A solution of 154 (1.597 g, 3.43 mmol, 1 eq.) and Hunig’s base (0.89 g, 6.86 mmol, 2eq.) 
in CH2Cl2 (6 mL) was cooled to 0oC. TMSOTf (0.915 g, 4.12 mmol, 1.2 eq.) was then added and 
the mixture was stirred at 0oC for 1h. The reaction was then quenched with sat. NaHCO3 (aq) (10 
mL). The layers were then separated. The aqueous layer was extracted with CH2Cl2 (5 mL) three 
times. The combined organic layer was washed with brine (10 mL), dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by silica gel chromatography (10-
50% EtOAc/Hexane) to yield 155 as a colorless oil (0.94 g, 75% yield). 1H NMR (500 MHz, 
Chloroform-d) δ 7.71 – 7.62 (m, 4H), 7.47 – 7.34 (m, 6H), 5.81 (dddd, J = 17.2, 10.1, 7.1, 1.4 Hz, 
1H), 5.10 (dt, J = 17.1, 1.4 Hz, 1H), 4.99 (dq, J = 10.1, 1.3 Hz, 1H), 3.63 – 3.49 (m, 3H), 3.44 (p, J 
= 6.3 Hz, 1H), 2.00 – 1.83 (m, 3H), 1.58 – 1.37 (m, 2H), 1.07 (d, J = 1.3 Hz, 9H). 13C NMR (126 
MHz, Chloroform-d) δ 141.83, 135.73, 133.79, 129.78, 127.82, 113.99, 67.12, 60.08, 59.15, 32.19, 
27.49, 27.04, 19.42. FTIR (CHCl3 film): 3071.08, 2959.23, 2930.31, 2857.51, 1589.06, 1471.9, 
1427.55, 1112.73 cm-1. HRMS: [M+H]+ calc. 366.2253, found 366.2264. 
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(2S,5S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-1-(2-((4S,5R)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-
yl)ethyl)-5-vinylpyrrolidine (157) 
 
A mixture of 155 (0.34 g, 0.93 mmol, 1 eq.), 15651 (0.33 g, 1 mmol, 1.1 eq.), Hunig’s base 
(0.24 g, 1.86 mmol, 2 eq.) in acetonitrile (10 mL) was heated to 80oC for 16h. The reaction was 
cooled down to 25oC and concentrated under reduced pressure. The residue was purified by silica 
gel chromatography (2-5% EtOAc/CH2Cl2) to yield 157 as a colorless oil (0.34 g, 70% yield). 1H 
NMR (500 MHz, Chloroform-d) δ 7.68 (dddd, J = 8.0, 6.5, 3.1, 1.4 Hz, 4H), 7.45 – 7.33 (m, 6H), 
5.73 (dddd, J = 16.9, 12.7, 10.2, 8.5 Hz, 2H), 5.23 – 5.05 (m, 4H), 4.40 (dd, J = 7.8, 6.3 Hz, 1H), 
4.12 – 4.08 (m, 1H), 3.65 (dd, J = 10.1, 4.1 Hz, 1H), 3.50 (ddd, J = 12.2, 9.7, 6.6 Hz, 2H), 3.07 (dp, 
J = 10.6, 3.6 Hz, 1H), 2.71 (ddd, J = 13.2, 9.0, 4.5 Hz, 1H), 2.60 (ddd, J = 12.4, 9.3, 7.0 Hz, 1H), 
2.03 – 1.93 (m, 1H), 1.83 – 1.74 (m, 1H), 1.56 (dddd, J = 15.6, 12.4, 9.1, 4.0 Hz, 2H), 1.48 – 1.41 
(m, 1H), 1.40 (s, 3H), 1.31 – 1.26 (m, 4H), 1.06 (d, J = 4.1 Hz,9H). 13C NMR (126 MHz, Chloroform-
d) δ 139.62, 135.74, 135.70, 135.68, 134.66, 133.91, 133.84, 129.68, 129.63, 127.79, 127.72, 
118.19, 116.13, 108.08, 79.82, 65.92, 65.25, 61.97, 45.15, 30.41, 29.63, 28.32, 26.99, 26.66, 
25.69, 19.33, 19.33. FTIR (CHCl3 film): 2931.75, 2857.51, 1472.38, 1428.03, 1112.24 cm-1. HRMS: 
[M+H]+ calc. 520.3247, found 520.3241. 
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 (3R,4S)-6-((2S,5S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-5-vinylpyrrolidin-1-yl)hex-1-ene-3,4-
diyl diacetate (158) 
 
Step 1: A solution of 157 (0.6 g, 1.15 mmol, 1 eq.), TsOH.H2O (0.5 g, 2.3 mmol, 2eq.) in MeOH (10 
mL) was stirred at 25oC under argon atmosphere for 16h. The solvent was removed under reduced 
pressure. The residue was dissolved in CH2Cl2 (10 mL) and neutralized with sat. aq. NaHCO3 (15 
mL). The layers were separated. The aqueous layer was extracted with CH2Cl2 (10 mL) three times. 
The combined organic layer was washed with brine (10 mL), dried over Na2SO4 and concentrated 
under reduced pressure. The resulting colorless oil was used in the next step without further 
purification.  
Step 2: The residue from step 1 was dissolved in CH2Cl2 (15 ml). Pyridine (1.9 ml), DMAP (0.014 
g, 0.115 mmol, 0.1 eq.) and AcCl (0.361 g, 4.6 mmol, 4eq.) were added to the solution. The resulting 
mixture was then stirred at 25oC for 6h. H2O (2 mL) was then added and the mixture was stirred 
further at 25oC for 15 min. The reaction was neutralized with sat. aq. NaHCO3 (10 mL). The mixture 
was extracted with EtOAc (10 mL) three times. The combined organic layer was washed with brine 
(10 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified 
by silica gel chromatography (10% EtOAc/Hexane) to yield 158 as a colorless oil (0.62 g, 96% 
yield). 1H NMR (500 MHz, Chloroform-d) δ 7.67 (ddt, J = 7.7, 6.0, 1.6 Hz, 4H), 7.49 – 7.35 (m, 6H), 
5.83 – 5.57 (m, 2H), 5.43 – 4.99 (m,4H), 3.65 – 3.37 (m, 2H), 3.05 (qd, J = 7.1, 4.1, 3.6 Hz, 1H), 
2.68 – 2.45 (m, 1H), 2.11 – 2.03 (m, 3H), 2.03 – 1.92 (m, 1H), 1.92 – 1.84 (m, 3H), 1.76 (ddd, J = 
9.3, 7.4, 3.1 Hz, 1H), 1.69 – 1.49 (m, 1H), 1.35 – 1.23 (m, 1H), 1.13 – 1.02 (m, 9H). 13C NMR (126 
MHz, Chloroform-d) δ170.43, 170.03 , 139.89 , 135.70 , 135.68 , 133.86, 133.76, 132.23 , 129.73 
92 
 
, 127.77 , 127.75 , 119.00 , 115.94 , 71.80 , 65.66 , 65.10 , 61.44 , 43.43 , 31.69 , 30.29 , 27.77 , 
26.96 , 26.74 , 20.95 , 19.30. FTIR (CHCl3 film): 3071.08, 2932.23, 2857.99, 1745.26, 1428.03, 
1371.14, 1243.86, 1225.54, 1111.76 cm-1. HRMS: [M+H]+ calc. 564.3145, found 564.3139. 
 
 (3S,7S,8R,10aS,Z)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-1,2,3,5,6,7,8,10a-
octahydropyrrolo[1,2-a]azocine-7,8-diyl diacetate (159) 
 
TsOH (0.015g, 0.088 mmol, 1 eq.) was added to a solution of 158 (0.05 g, 0.088 mmol, 1 
eq.) in CH2Cl2 (5 mL). The mixture was stirred at 25oC for 30 min before concentrated under 
reduced pressure. The residue was dissolved in toluene (15 mL) and degassed by bubbling with 
argon gas for 30 min. Grubbs’ catalyst (2nd Gen) (0.008g, 0.0088 mmol, 0.1 eq.) was then added. 
The mixture was stirred at 25oC under argon atmosphere for 24h. The mixture was concentrated 
under reduced pressure. Sat. NaHCO3 (aq) (5 mL) was then added. The mixture was then extracted 
with CH2Cl2 (5mL) three times. The combined organic layer was then washed with brine (5 mL), 
dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica 
gel chromatography (gradient 15-100% EtOAc/Hexane) to yield 159 as a colorless oil (0.021g, 45% 
yield). 1H NMR (500 MHz, Chloroform-d) δ 7.77 – 7.65 (m, 4H), 7.44 – 7.32 (m, 6H), 5.72 (p, J = 
6.2 Hz, 2H), 5.37 (dq, J = 13.4, 4.0 Hz, 2H), 3.94 (dd, J = 9.9, 5.9 Hz, 1H), 3.65 (dd, J = 10.1, 4.8 
Hz, 1H), 3.50 (dd, J = 10.1, 6.1 Hz, 1H), 2.73 (dt, J = 14.0, 8.2 Hz, 3H), 2.23 – 2.12 (m, 1H), 2.11 
(s, 2H), 2.04 (s, 3H), 1.90 – 1.73 (m, 2H), 1.70 – 1.55 (m, 1H), 1.35 – 1.17 (m, 2H), 1.07 (s, 9H), 
0.89 (q, J = 6.6 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 170.15, 170.03, 135.57, 135.52, 
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133.75, 133.63, 129.53, 129.51, 129.06, 128.97, 127.56, 73.40, 72.25, 67.15, 63.58, 57.77, 41.72, 
29.83, 29.04, 26.81, 26.79, 21.03, 20.99, 19.17. FTIR (CHCl3 film): 3071.08, 2932.23, 2857.99, 
1744.3 1428.03, 1371.14, 1225.54, 1111.76 cm-1. HRMS: [M+H]+ calc. 536.2832, found 536.2806. 
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CHAPTER 3. ANTAGONISTS OF THE F PROSTANOID (FP) RECEPTER AS A NOVEL DRUG 
TARGET FOR HYPERTENSION TREATMENT 
 
3.1. Causes and treatments of hypertension 
High blood pressure is one of major causes of death in the US and around the world 
because it can lead to other deadly conditions, such as heart failure, stroke and kidney failure. 
Recent updates from the American Heart Association state that the proportion of U.S. adults who 
have high blood pressure may reach 41% by 2030.52 The development of new chemotherapeutic 
strategies for the treatment and prevention of hypertension is therefore critical. 
Blood pressure regulation is complex and involves many factors and systems in our 
bodies.53 The renin-angiotensin system (RAS) is one of the well-known systems. Shown in 
Figure3.1, angiotensin II (Ang II) is a vasoconstrictor that causes blood pressure elevation. The 
production of Ang II is controlled by two enzymes called renin and angiotensin converting enzyme 
(ACE). There are currently three classes of marketed drugs for the treatment of hypertension via 
the inhibition of the RAS: ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and direct 
renin inhibitors.54 However, most of these are taken in combination with other drugs and have 
potential adverse effects. It is therefore important to develop novel targets for hypertension 
treatment. 
 
  
 
 
 
 
Figure 3.1 Blood pressure regulation through the renin-angiotensin system (RAS).54  
 
 
PGF2α
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3.2. FP receptor inhibition as a novel target for treatment of hypertension 
Prostaglandin F2α (PGF2α) is a naturally occurring prostaglandin that specifically binds to 
the FP receptor, a G protein-coupled receptor.  It  exists in many organs and  affects a wide range 
of body functions,55,56,57 such as uterine contraction, water and electrolyte reabsorption, 
vasoconstriction, renin secretion and blood pressure regulation. 
In 2009, the FitzGerald group in the Department of Pharmacology at the University of Pennsylvania 
discovered that the activation of PGF2α increased plasma renin concentration and consequently led 
to the production of Ang II and blood pressure elevation (Figure 3.1).58 Thus, antagonists of FP 
receptor can function as novel agents for reduction of blood pressure and the treatment of 
hypertension.  
Collaborating with the FitzGerald group to prove this hypothesis, we have designed and 
synthesized small molecules to serve as antagonists of the FP receptor and have screened them 
as potential agents to reduce blood pressure. 
 
3.3 Lead compound and previous efforts for FP antagonists  
  Only a few FP antagonists have been previously described in the scientific literature (e.g. 
AL-8810 and THG113), which underscores the challenge in the development of new FP 
antagonists.59,60,61More recently, a non-prostaglandin small molecule, AS604872, was reported and 
patented as an orally active, potent and selective antagonist of the FP receptor for the arrest of 
preterm labor. AS604872 had Ki of 35±4 nM and no agonist activity for the human FP receptor.55 
However, this compound was not sufficiently soluble in aqueous solution for IV administration in 
rats. Using AS604872 as the lead compound, we have designed and synthesized derivatives of 
AS604872 in order to improve the solubility and FP antagonist activity, with the long-term goal of 
the development of for pressure-lowering agents. 
For the first set of AS604872 derivatives, Timothy S. Bush, a former student in our research 
group, made variations at the sulfonamide part (compound 162-171, Table 3.1) and found that they 
were not active or not as potent as the lead compound. Moreover, replacing the thiazolidine core 
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with proline (compound 172-175, Table 3.2) to remove the easily oxidized sulfur atom and facilitate 
synthetic accessibility also led to analogs with reduced potency. This suggests that the biaryl and 
sulfur atom in the thiazolidine ring are important to the antagonist activity. 
 
 
Table 3.1 Structures and PGF2α antagonist activities of the lead compound, AS604872, and 
previous thiazolidine analogs (ND= not determined)  
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Table 3.2 Structures and PGF2α antagonist activities of the previous proline analogs. (ND=not 
determined) 
 
3.4 Structural design and synthetic plans for PGF2α antagonist analogs 
For a Structure-Activity Relationship (SAR) study of AS604872, we envisioned that 
AS604872 could be divided into 3 parts; sulfonamide (A), thiazolidine core (B) and amide branch 
(C). The derivatives of each part could be combined by peptide coupling and N-sulfonylation 
reactions, shown in Figure 3.2. 
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Figure 3.2 Structure analysis of AS604872. 
 
To screen for the more potent and more water soluble compounds, we envisioned 
variations of each of the three portions of the parent structure as outlined below:  
Variation at the sulfonamide part (A) 
The previous work by Bush suggests that the biaryl sulfonamide is crucial for activity. We 
envisioned that the biaryl portion could be diversified by Suzuki-Miyaura cross-coupling Reaction 
of the bromophenyl (177) and various heteroaromatic- and substituted phenyl- boronic acids (178), 
shown in Figure 3.3.  
 
 
Figure 3.3 Synthetic strategy for the variation at the sulfonamide moiety (A). 
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Variation at the thiazolidine core (B) 
The sulfur atom in the lead compound AS604872 could be subject to oxidation under 
physiological conditions. Moreover, loss of the chiral center at C2 could happen via ring opening of 
the thiazolidine ring. We therefore planned to replace the thiazolidine core with amino acid 
derivatives which could improve stability as well as water solubility. The synthesis of these analogs 
could be achieved in the same fashion (peptide coupling and N-sulfonylation) as the synthesis of 
the lead compound, AS604872, shown in Scheme 3.1. 
 
Scheme 3.1 Synthetic plan for the variation at the thiazolidine core (B).  
 
Variation at the amide portion (C) 
To study the effect of phenyl and pyridine ring on the amide portion, the thiazolidine 
compound could be diversified by peptide coupling with different amines. 
 
Scheme 3.2 Synthetic plan for the variation at the amide portion (C).  
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3.5. Synthesis of the designed PGF2α antagonist analogs 
Synthesis of the chiral amine (180) 
Following precedent literature,62 the synthesis of chiral amines 180 using Ellman’s chiral 
sulfinamide methodology was straightforward and the requisite amines were successfully obtained 
in good yield (Scheme 3.3). The commercially available aldehyde 186 was condensed with the 
chiral auxiliary I-(+)-2-methyl-2-propane sulfinamide to form the chiral sulfinamide 187. The 
stereoselective attack of of PhMgBr on 187 yielded the corresponding enantiomeric pure amine 
180 after the acid-catalyzed removal of the chiral auxiliary.  
 
 
 
Scheme 3.3 Synthesis of the chiral amine (180) by using Ellman’s chiral 100ulfonamide. 
 
Synthesis of the enantiopure N-protected thiazolidine carboxylic core (191) 
Following  literature precedent,59 the enantiopure carboxylic acid 190 was prepared from 
the cyclization of cystamine 188 and glyoxylic acid 189 in the present of (D)-(-)-tartaric acid in 
moderate yield. Unfortunately, Boc protection of the free amine before the peptide coupling step 
was not straightforward. We found that treating the chiral carboxylic acid 190 with different sources 
of the Boc  group and a variety of different reaction conditions led to the racemic mixture of 191 
(Scheme3.4). This was similar to the observation reported by Bush. A mechanism for the 
epimerization is shown in Scheme 3.5.63 However, this problem was solved by the preparation of 
the thiazolidine ethyl ester 19664 which could be Boc protected and hydrolyzed to the key compound 
191 without loss of stereochemistry integrity (Scheme 3.5). 
 
 
101 
 
 
 
Scheme 3.4 Initial efforts for the synthesis of the enantiopure N-protected thiazolidine carboxylic 
core (191).  
 
 
 
Scheme 3.5 Propose mechanism for epimerization of the thiazolidine carboxylic acid (190). 
 
 
Scheme 3.6 Synthesis of the the enantiopure thiazolidine carboxylic core (191). 
 
 
102 
 
Synthesis of the PGF2α antagonist analogs 
The general synthetic route for the lead compound, AS604872, and its derivatives is shown 
in Scheme 3.7. The N-protected thiazolidine or N-protected amino acids 179 was coupled with the 
prepared chiral amine 180. After Boc-deprotection, the free amine in 198 was subsequently 
sulfonylated with p-bromosulfonylchloride 199 to give the corresponding arylbromide 200. The 
preparation of a variety of biphenyl derivatives 201 in rapid fashion was performed by Suzuki-
Miyaura coupling of the arylbromide 200 with various aryl trifluoroborates or aryl boronicacids.  
 
Scheme 3.7 Synthesis of the lead compound, AS604872, and its derivatives. 
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3.6 Biological evaluations of PGF2α antagonist analogs  
Collaborating with the FitzGerald group, we evaluated the FP antagonist activities of our 
analogs by an assay that measures the change in inositol triphosphate (IP3) signaling when PGF2α 
interacts with FP receptor. Therefore, FP agonists would lead to an increase in IP3 signaling. An 
FP antagonist would lead to a decrease in IP3 signaling. The IC50 shown here was measured at a 
PGF2α concentration of 100 nM.  
Although most biaryl derivatives with different heteroaromatic and substituted phenyl 
groups (Table 3.3) showed lower FP antagonist activity than AS604872, compound 205 was about 
3 times more potent than the lead compound. Similarly, the corresponding proline derivative 213 
was about 4 times more potent than 172. This intriguing result led us to further study the effect of 
N-atom position. As shown in Table 3.4, the synthetically accessible biaryl proline analogs were 
prepared. Having a nitrogen atom at the 4-position in compound 215 destroyed the activity of the 
compound. Interestingly, having one extra nitrogen atom, as shown at the 5-position in compound 
214, also led to the loss of antagonist activity. This result is somewhat correlated to the difference 
in IC50 of compound 210 and 212. These data suggest that there might be an important interaction 
of the C-H bond at the 4-position of these ligands to the target or that steric hindrance at the 4-
position might significantly affects the interactions of compound to the target.   
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Table 3.3 FP antagonist activity (IC50) of biaryl thiazolidine derivatives.  
Note: 1) ND = not determined 2) None of them showed agonist activity. 
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Table 3.4 FP antagonist activity (IC50) of biaryl proline derivatives. 
Note: 1) ND = not determined 2) None of them showed agonist activity. 
 
For the variation of the amide branch, compound 229 and 230 showed a significant loss in 
PGF2α antagonist activity, compared to the lead compound AS604872. The phenyl ring proved to 
be more important than the pyridine ring, from the IC50 values shown in Figure 3.5. We therefore 
kept the phenyl ring for the variation at the thiazolidine core to simplify the synthesis (compound 
220 to 228). Amino acids were thought to be a good choice because they are readily available and 
could potentially improve the solubility in aqueous media. Unfortunately, all of them (compound 216 
to 228) led to complete loss of antagonist potency (Figure3.4). This suggests that the thiazolidine 
ring is critical for the potency of these compounds.   
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Figure 3.4 FP antagonist activity (IC50) of the amino acid derivatives 
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Figure 3.5  FP antagonist activity (IC50) for derivatives with variation of the amide branch. 
 
 3.7. Conclusions 
In conclusion, we have designed, synthesized and evaluated analogs of AS604872 as 
PGF2α antagonists. Our preliminary SAR studies indicate that the lead structure is very sensitive to 
substitution. Among the prepared analogs, only 205 exhibited improvement in PGF2α antagonist 
activity in vitro by ca. 3x lower IC50 than the one of AS604872. However, diversification of the 
structure in an effort to improve water solubility led to the loss of potency. The SAR study showed 
that the substituents at the 4-position of the biphenyl portions (207-211 and 215) caused the loss 
in potency more than the one at the 3-position (205 and 212). This result suggests that the C-H 
bond or the steric hindrance at the 4-position may be an important factor for the interaction between 
the compound and target. Replacement of the thiazolidine ring with other ring systems (216-228) 
also led to the loss of antagonist activity. This result suggests that the orientation of the biphenyl 
and the chiral amine moieties is crucial for the activity. 
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3.8 General method and experimental procedures  
3.8.1. General information 
Unless otherwise stated, all reagents were purchased from Sigma Aldrich, Alfa Aesar, 
Acros Organic or TCI America and used without further purification.1H and 13C NMR spectra were 
recorded on Bruker AVII500B (500 MHz) and DRX-500 (500 MHz) spectrometers. Chemical shifts 
are reported relative to the solvent resonance peak δ 7.26 (CDCl3) for 1H NMR and δ 77.16 (CDCl3) 
for 13C. Infrared spectra were recorded on a NaCl plate using a Perkin-Elmer 1600 series Fourier 
transform spectrometer. High-resolution mass spectra were obtained by Dr. Rakesh Kohli at the 
University of Pennsylvania Mass Spectrometry Service Center. 
 
3.8.2. General procedure for the synthesis of PGF2α antagonist analogs   
Suzuki Coupling of the bromoaryl 200 and a variety of RBF3K  (for compounds 202-208) 
 
 
 
Compound 200 (1 eq.), Pd(OAc)2 (3mol%), RuPhos (6mol%), RBF3K (1.05 eq.) and  
Na2CO3 (2eq.) were placed in a sealable glass tube and purged with argon gas. Degassed EtOH 
(0.2M) was then added. The mixture was then heated up to 85oC for 12-16h (monitored by TLC). 
The reaction was cooled to 25oC and then filtered through a thin pad of Celite, which was washed 
with 25% MeOH/EtOAc. The filtrate was concentrated under reduced pressure and purified by silica 
gel chromatography (50%EtOAc/Hexane) to yield the corresponding biphenyl compounds. 
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Suzuki Coupling of the bromoaryl 200 and a variety of RB(OH)2 (for compounds 209-215)  
 
 
Compound 200 (1 eq.), Pd(OAc)2 (6mol%), BINAP (12mol%), RB(OH)2 (1.1 eq.) and  
K3PO4 (2eq.) were placed in a sealable glass tube and purged with argon gas. Degassed CH3CN 
(0.2M) was then added. The mixture was then heated to 80oC for 12-16h (monitored by TLC, mobile 
phase 50% EtOAc/Hexane). The reaction was cooled to 25oC and then filtered through a thin pad 
of Celite, which was washed with 25%MeOH/EtOAc. The filtrate was concentrated under reduced 
pressure and purified by silica gel chromatography (50%EtOAc/Hexane) to yield the corresponding 
biphenyl compounds. 
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3.8.3. Characterization data for PGF2α antagonist analogs 
(S)-3-((4-(furan-2-yl) phenyl) sulfonyl)-N-((R)-phenyl(pyridin-2-yl)methyl)thiazolidine-2-
carboxamide (202) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.61 – 8.55 (m, 2H), 7.90 (d, J = 8.6 Hz, 2H), 7.84 (s, 1H), 7.65 
– 7.58 (m, 3H), 7.53 (t, J = 1.8 Hz, 1H), 7.33 (d, J = 6.8 Hz, 2H), 7.28 (t, J = 7.1 Hz, 2H), 7.25 – 
7.17 (m, 3H), 6.73 (s, 1H), 6.08 (d, J = 7.4 Hz, 1H), 5.48 (s, 1H), 4.06 (dt, J = 11.5, 5.5 Hz, 1H), 
3.74 (ddd, J = 11.7, 7.6, 6.0 Hz, 1H), 2.96 (dt, J = 10.9, 5.4 Hz, 1H), 2.59 (ddd, J = 10.6, 7.6, 6.0 
Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 168.07, 158.48, 149.14, 144.55, 141.17, 140.19, 
137.04, 135.05, 128.80, 128.65, 127.73, 127.35, 126.52, 124.99, 122.81, 122.68, 108.62, 77.36, 
65.33, 57.75, 52.80, 31.66. FTIR (CHCl3 film): 2925.48 (sp3 C-H str), 1678.73 (amide I C=O), 
1508.06 (amide II C=O), 1349.93 (sym SO2), 1159.97 (asym SO2) cm-1. [α]D23.9 ᴼC= -120.8ᴼ (c 2.07, 
CHCl3). HRMS: [M+H]+ calc. 506.1208, found 506.1204. 
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(S)-N-((R)-phenyl(pyridin-2-yl)methyl)-3-((4-(thiophen-2-yl)phenyl)sulfonyl)thiazolidine-2-
carboxamide (203) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.60 – 8.53 (m, 2H), 7.89 (d, J = 8.6 Hz, 2H), 7.73 (d, J = 8.6 
Hz, 2H), 7.63 (tt, J = 7.7, 1.7 Hz, 1H), 7.45 (dd, J = 3.7, 1.1 Hz, 1H), 7.41 (dd, J = 5.1, 1.2 Hz, 1H), 
7.35 – 7.27 (m, 4H), 7.24 – 7.17 (m, 4H), 7.14 (dd, J = 5.0, 3.7 Hz, 1H), 6.08 (d, J = 7.4 Hz, 1H), 
5.49 (s, 1H), 4.06 (ddd, J = 11.9, 6.1, 4.9 Hz, 1H), 3.74 (ddd, J = 11.9, 7.6, 6.0 Hz, 1H), 2.98 (ddd, 
J = 10.9, 6.0, 4.9 Hz, 1H), 2.62 (ddd, J = 10.8, 7.6, 6.1 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) 
δ 168.05, 158.45, 149.12, 141.87, 141.15, 139.73, 137.08, 135.32, 128.81, 128.72, 128.68, 127.76, 
127.37, 126.37, 125.48, 122.83, 122.69, 77.36, 65.31, 57.75, 52.77, 31.70. FTIR (CHCl3 film): 
2925.48 (sp3 C-H str), 1678.73 (amide I C=O), 1496.49 (amide II C=O), 1348.96 (sym SO2), 
1163.83 (asym SO2) cm-1. [α]D23.9 ᴼC= -111.5ᴼ (c 1.7, CHCl3). HRMS: [M+H]+ calc. 522.0980, found 
522.0974.  
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(S)-3-((4-(3,5-dimethylisoxazol-4-yl)phenyl)sulfonyl)-N-((R)-phenyl(pyridin-2-
yl)methyl)thiazolidine-2-carboxamide (204) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.64 – 8.53 (m, 2H), 7.98 (d, J = 8.6 Hz, 2H), 7.65 – 7.61 (m, 
1H), 7.42 (d, J = 8.6 Hz, 2H), 7.33 (ddt, J = 4.4, 3.3, 1.5 Hz, 2H), 7.30 – 7.26 (m, 2H), 7.24 – 7.18 
(m, 4H), 6.08 (d, J = 7.4 Hz, 1H), 5.49 (s, 1H), 4.08 – 4.02 (m, 1H), 3.77 (ddd, J = 11.8, 7.2, 6.1 Hz, 
1H), 3.03 (dt, J = 11.1, 5.7 Hz, 1H), 2.68 (ddd, J = 10.9, 7.3, 6.1 Hz, 1H), 2.43 (s, 3H), 2.28 (d, J = 
1.7 Hz, 3H).13C NMR (126 MHz, Chloroform-d) δ 167.97, 158.40, 158.25, 149.11, 141.17, 137.09, 
136.53, 136.24, 129.83, 128.81, 128.55, 127.77, 127.33, 122.85, 122.72,  115.32, 77.36, 65.18, 
57.78, 52.76, 31.68, 11.94, 11.04. FTIR (CHCl3 film): 2925.48 (sp3 C-H str), 1678.73 (amide I C=O), 
1499.38 (amide II C=O), 1351.86 (sym SO2), 1165.76 (asym SO2) cm-1. [α]D23.9 ᴼC= -124.9ᴼ (c 0.1, 
CHCl3). HRMS: [M+H]+ calc. 535.1474, found 535.1465.  
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(S)-N-((R)-phenyl(pyridin-2-yl)methyl)-3-((4-(pyridin-3-yl)phenyl)sulfonyl)thiazolidine-2-
carboxamide (205) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.86 (d, J = 2.4 Hz, 1H), 8.68 (dd, J = 4.9, 1.6 Hz, 1H), 8.60 – 
8.53 (m, 2H), 8.02 (d, J = 8.7 Hz, 2H), 7.90 (ddd, J = 8.0, 2.4, 1.7 Hz, 1H), 7.75 – 7.71 (m, 2H), 
7.63 (td, J = 7.6, 1.8 Hz, 1H), 7.43 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 7.33 (d, J = 7.1 Hz, 2H), 7.28 (d, 
J = 7.1 Hz, 1H), 7.25 – 7.18 (m, 3H), 6.08 (d, J = 7.4 Hz, 1H), 5.50 (s, 1H), 4.06 (ddd, J = 11.5, 6.1, 
5.1 Hz, 1H), 3.77 (ddd, J = 11.8, 7.3, 6.1 Hz, 1H), 3.01 (ddd, J = 11.0, 6.0, 5.1 Hz, 1H), 2.67 (ddd, 
J = 10.9, 7.3, 6.1 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 167.98, 158.42, 149.90, 149.11, 
148.42, 141.15, 137.10, 136.79, 134.80, 128.81, 128.15, 127.76, 127.35, 123.94, 122.85, 122.73, 
77.36, 65.20, 57.76, 52.75, 31.70. FTIR (CHCl3 film): 2925.48 (sp3 C-H str), 1678.73 (amide I C=O), 
1498.42 (amide II C=O), 1351.86 (sym SO2), 1165.76 (asym SO2) cm-1. [α]D23.9 ᴼC= -133.4ᴼ (c 0.07, 
CHCl3). HRMS: [M+H]+ calc. 517.1368, found 517.1371.  
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(S)-N-((R)-phenyl(pyridin-2-yl)methyl)-3-((4-(pyrimidin-5-yl)phenyl)sulfonyl)thiazolidine-2-
carboxamide (206) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 2.70 (dt, J=10.99, 6.56 Hz, 1 H) 3.04 (dt, J=10.91, 5.68 Hz, 1 
H) 3.78 (dt, J=18.01, 6.10 Hz, 1 H) 4.03 - 4.08 (m, 1 H) 5.50 - 5.55 (m, 1 H) 6.08 (d, J=7.32 Hz, 1 
H) 7.19 - 7.25 (m, 3 H) 7.29 (d, J=7.02 Hz, 2 H) 7.32 - 7.34 (m, 2 H) 7.73 (d, J=8.54 Hz, 2 H) 8.06 
(d, J=8.24 Hz, 2 H) 8.59 (d, J=3.97 Hz, 1 H) 8.60 (br. s., 1 H) 8.98 (s, 2 H) 9.29 (s, 1 H). 13C NMR 
(126 MHz, Chloroform-d) δ 31.73, 52.66, 57.78, 65.14, 107.57, 122.78, 122.90, 127.37, 127.81, 
128.05, 128.85, 129.12, 137.13, 137.96, 139.71, 141.18, 149.14, 155.26, 156.97, 158.39, 167.87. 
FTIR (CHCl3 film): 2926.45 (sp3 C-H str), 1676.8 (amide I C=O), 1497.45 (amide II C=O), 1348.96 
(sym SO2), 1166.72 (asym SO2) cm-1. [α]D23.9 ᴼC= -149.9ᴼ (c 0.07, CHCl3). HRMS: [M+H]+ calc. 
518.1321, found 518.1329.  
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(S)-3-((4'-fluoro-[1,1'-biphenyl]-4-yl)sulfonyl)-N-((R)-phenyl(pyridin-2-yl)methyl) 
thiazolidine-2-carboxamide (207) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.65 – 8.55 (m, 2H), 7.96 (d, J = 9.1 Hz, 2H), 7.68 (d, J = 9.1 
Hz, 2H), 7.65 – 7.60 (m, 1H), 7.57 (ddd, J = 10.0, 5.1, 2.6 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.28 
(d, J = 7.2 Hz, 2H), 7.24 – 7.15 (m, 5H), 6.10 (d, J = 7.4 Hz, 1H), 5.50 (s, 1H), 4.06 (ddd, J = 11.5, 
6.1, 5.1 Hz, 1H), 3.77 (ddd, J = 11.9, 7.4, 6.0 Hz, 1H), 2.98 (ddd, J = 11.0, 5.9, 5.1 Hz, 1H), 2.63 
(ddd, J = 10.9, 7.4, 6.1 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 168.16, 158.46, 149.14, 
145.68, 141.09, 137.10, 135.64, 129.25, 129.18, 128.80, 128.60, 127.92, 127.74, 127.33, 122.87, 
122.72, 116.33, 116.16, 65.27, 57.78, 52.85, 31.65. FTIR (CHCl3 film): 2925.48 (sp3 C-H str), 
1674.87 (amide I C=O), 1517.7 (amide II C=O), 1351.86 (sym SO2), 1161.9 (asym SO2) cm-1. 
[α]D23.9 ᴼC= -148.9ᴼ (c 0.07, CHCl3). HRMS: [M+H]+ calc. 534.1321, found 534.1317.  
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(S)-N-((R)-phenyl(pyridin-2-yl)methyl)-3-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-
yl)sulfonyl)thiazolidine-2-carboxamide (208) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.63 – 8.57 (m, 2H), 8.01 (d, J = 8.8 Hz, 2H), 7.77 – 7.67 (m, 
7H), 7.64 (td, J = 7.7, 1.8 Hz, 1H), 7.33 (tt, J = 5.3, 1.4 Hz, 2H), 7.30 – 7.27 (m, 2H), 7.26 – 7.17 
(m, 4H), 6.10 (d, J = 7.5 Hz, 1H), 5.51 (s, 1H), 4.06 (dt, J = 11.6, 5.7 Hz, 1H), 3.79 (ddd, J = 11.8, 
7.2, 6.1 Hz, 1H), 3.01 (dt, J = 11.1, 5.6 Hz, 1H), 2.66 (ddd, J = 10.9, 7.2, 6.1 Hz, 1H). 13C NMR 
(126 MHz, Chloroform-d) δ 168.12, 158.40, 149.09, 145.14, 141.06, 137.17, 136.71, 128.83, 
128.71, 128.34, 127.88, 127.78, 127.33, 126.19, 126.16, 122.90, 122.77, 65.21, 57.79, 52.81, 
31.66. FTIR (CHCl3 film): 2925.48 (sp3 C-H str), 1679.69 (amide I C=O), 1504.2 (amide II C=O), 
1352.82 (sym SO2), 1165.76 (asym SO2) cm-1. [α]D23.9 ᴼC= -116.7ᴼ (c 0.05, CHCl3). HRMS: [M+H]+ 
calc. 584.1289, found 584.1293.  
 
 
 
 
 
 
 
117 
 
(S)-3-((4'-hydroxy-[1,1'-biphenyl]-4-yl)sulfonyl)-N-((R)-phenyl(pyridin-2-yl)methyl) 
thiazolidine-2-carboxamide (209) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.64 – 8.59 (m, 2H), 7.91 – 7.89 (m, 2H), 7.69 – 7.60 (m, 4H), 
7.47 – 7.43 (m, 2H), 7.36 – 7.27 (m, 3H), 7.25 – 7.18 (m, 2H), 6.95 – 6.86 (m, 3H), 6.11 (d, J = 7.5 
Hz, 2H), 5.49 (s, 1H), 4.05 (dt, J = 11.5, 5.6 Hz, 1H), 3.80 – 3.72 (m, 1H), 3.01 (dt, J = 11.1, 5.6 
Hz, 1H), 2.67 (ddd, J = 10.9, 7.3, 6.0 Hz, 1H). FTIR (CHCl3 film): 3334.32, 2923.56, 1652.7, 1520.6, 
1349.93, 1268.93, 1162.87 cm-1. HRMS: [M+Na]+ calc. 554.1184, found 554.1202. 
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methyl 4'-(((S)-2-(((R)-phenyl(pyridin-2-yl)methyl)carbamoyl)thiazolidin-3-yl)sulfonyl)-[1,1'-
biphenyl]-4-carboxylate (210) 
 
1H NMR (500 MHz, Chloroform-d) δ 8.61 – 8.54 (m, 2H), 8.17 – 8.12 (m, 2H), 8.02 – 7.98 (m, 2H), 
7.78 – 7.73 (m, 2H), 7.69 – 7.65 (m, 2H), 7.63 (td, J = 7.6, 1.7 Hz, 1H), 7.33 (tt, J = 6.0, 1.5 Hz, 
2H), 7.30 – 7.27 (m, 1H), 7.25 – 7.18 (m, 3H), 6.08 (d, J = 7.4 Hz, 1H), 5.50 (s, 1H), 4.09 – 4.03 
(m, 1H), 3.96 (s, 3H), 3.77 (ddd, J = 12.0, 7.5, 6.1 Hz, 1H), 3.00 (ddd, J = 11.0, 6.0, 5.0 Hz, 1H), 
2.65 (ddd, J = 10.9, 7.4, 6.1 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 168.03, 166.74, 158.43, 
149.06, 145.45, 143.30, 136.63, 130.47, 130.40, 128.83, 128.65, 128.63, 128.32, 127.78, 127.51, 
127.40, 127.37, 122.88, 122.74, 76.91, 65.25, 57.77, 52.79, 52.44, 31.72. FTIR (CHCl3 film): 
3353.12, 1720.19, 1682.59, 1504.69, 1283.39, 1166.24 cm-1.  HRMS: [M+H]+ calc. 574.1470, found 
574.1459. 
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(S)-3-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)sulfonyl)-N-((R)-phenyl(pyridin-2-
yl)methyl)thiazolidine-2-carboxamide (211) 
 
1H NMR (500 MHz, Chloroform-d) δ 8.64 – 8.57 (m, 2H), 7.90 (dd, J = 8.6, 1.8 Hz, 2H), 7.69 (dq, J 
= 8.9, 2.4 Hz, 2H), 7.58 – 7.50 (m, 2H), 7.39 – 7.32 (m, 1H), 7.32 – 7.27 (m,3H), 7.25 – 7.16 (m, 
3H), 6.82 (d, J = 8.4 Hz, 2H), 6.09 (d, J = 7.5 Hz, 1H), 5.50 (d, J = 3.3 Hz, 1H), 4.10 – 4.05 (m,1H), 
3.74 (ddd, J = 11.7, 7.7, 5.9 Hz, 1H), 3.04 (s, 6H), 2.96 (dt, J = 10.8, 5.4 Hz, 1H), 2.60 (ddd, J = 
10.7, 7.7, 5.9 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 168.30, 158.54, 149.05, 146.72, 
141.10, 137.20, 133.75, 130.42, 128.85, 128.55, 128.19, 127.78, 127.41, 126.65, 122.89, 122.72, 
112.84, 65.40, 57.80, 52.93, 40.66, 31.73. FTIR (CHCl3 film): 2922.59, 1682.59, 1506.13, 1352.82, 
1160.94 cm-1. HRMS: [M+H]+ calc. 559.1838, found 559.1838. 
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methyl 4'-(((S)-2-(((R)-phenyl(pyridin-2-yl)methyl)carbamoyl)thiazolidin-3-yl)sulfonyl)-[1,1'-
biphenyl]-3-carboxylate (212) 
 
1H NMR (500 MHz, Chloroform-d) δ 8.60 (ddd, J = 5.0, 1.8, 0.9 Hz, 1H), 8.57 (d, J = 7.6 Hz, 1H), 
8.29 (t, J = 1.8 Hz, 1H), 8.10 (dt, J = 7.8, 1.4 Hz, 1H), 8.03 – 7.97 (m, 2H), 7.79 (ddd, J = 7.8, 2.0, 
1.1 Hz, 1H), 7.77 (s, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.57 (t, J = 7.8 Hz, 1H), 7.37 – 7.32 (m, 
2H), 7.31 – 7.27 (m, 3H), 7.25 – 7.18 (m, 2H), 6.11 (d, J = 7.5 Hz, 1H), 5.51 (s, 1H), 4.09 – 4.01 
(m, 1H), 3.97 (s, 3H), 3.79 (ddd, J = 11.8, 7.4, 6.1 Hz, 1H), 3.03 (dt, J = 11.0, 5.6 Hz, 1H), 2.66 
(ddd, J = 10.9, 7.3, 6.1 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 168.18, 166.76, 158.38, 
148.72, 145.59, 139.37, 136.35, 131.78, 131.24, 129.87, 129.40, 128.89, 128.67, 128.64, 128.18, 
127.87, 127.43, 123.08, 122.86, 65.22, 60.53, 57.76, 52.83, 52.50, 31.71. FTIR (CHCl3 film): 
2951.04, 1721.16, 1684.03, 1506.61, 1248.2, 1165.76 cm-1.  HRMS: [M+H]+ calc. 574.1470, found 
574.1477. 
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(S)-N-((R)-phenyl(pyridin-2-yl)methyl)-1-((4-(pyridin-3 -yl)phenyl)sulfonyl)pyrrolidine-2-
carboxamide (213) 
 
1H NMR (500 MHz, Chloroform-d) δ 8.85 (s, 1H), 8.68 (d, J = 7.5 Hz, 1H), 8.65 (dd, J = 4.9, 1.6 Hz, 
1H), 8.59 (d, J = 4.7 Hz, 1H), 8.01 – 7.95 (m, 2H), 7.88 (dt, J = 8.0, 2.1 Hz, 1H), 7.71 (d, J = 8.3 
Hz, 2H), 7.60 (td, J = 7.6, 1.8 Hz, 1H), 7.43 – 7.36 (m, 3H), 7.26 (dt, J = 16.3, 7.7 Hz, 2H), 7.21 – 
7.13 (m, 2H), 6.11 (d, J = 7.5 Hz, 1H), 4.25 (dd, J = 8.7, 3.0 Hz, 1H), 3.63 (ddd, J = 10.1, 7.1, 3.1 
Hz, 1H), 3.32 (td, J = 9.7, 6.3 Hz, 1H), 2.16 (ddt, J = 12.0, 6.0, 2.8 Hz, 1H), 1.85 – 1.74 (m, 1H), 
1.68 (dtd, J = 10.7, 8.0, 7.0, 4.2 Hz, 2H). 13C NMR (126 MHz, Chloroform-d) δ 170.29, 158.95, 
149.79, 149.29, 148.38, 142.78, 141.29, 136.85, 136.08, 134.71, 134.66, 128.76, 128.69, 127.94, 
127.54, 127.29, 123.84, 122.48, 62.68, 57.90, 49.88, 30.47, 24.52. FTIR (CHCl3 film): 3386.39, 
3055.66, 1953.45, 1671.98, 1508.061347.03, 1162.87 cm-1. HRMS: [M+H]+ calc. 499.1804, found 
499.1794. 
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(S)-N-((R)-phenyl(pyridin-2-yl)methyl)-1-((4-(pyrimidin-5-yl)phenyl)sulfonyl)pyrrolidine-2-
carboxamide (214) 
 
1H NMR (500 MHz, Chloroform-d) δ 9.26 (s, 1H), 8.96 (s, 2H), 8.65 (d, J = 7.5 Hz, 1H), 8.58 (dd, J 
= 4.9, 1.6 Hz, 1H), 8.02 (d, J = 8.1 Hz, 2H), 7.71 (d, J = 8.1 Hz, 2H), 7.60 (td, J = 7.8, 1.8 Hz, 1H), 
7.37 (d, J = 7.6 Hz, 2H), 7.30 – 7.21 (m, 3H), 7.21 – 7.12 (m, 2H), 6.10 (d, J = 7.5 Hz, 1H), 4.25 
(dd, J = 8.5, 3.0 Hz, 1H), 3.63 (ddd, J = 10.1, 7.2, 3.1 Hz, 1H), 3.31 (td, J = 9.7, 6.2 Hz, 1H), 2.16 
(ddt, J = 10.8, 8.1, 3.9 Hz, 1H), 1.86 – 1.76 (m, 1H), 1.69 (td, J = 10.9, 9.0, 5.3 Hz, 2H). 13C NMR 
(126 MHz, Chloroform-d) δ 170.17, 158.86, 158.52, 155.14, 149.26, 141.28, 137.20, 136.87, 
129.03, 128.69, 127.85, 127.55, 127.29, 122.53, 122.51, 62.67, 57.85, 49.84, 30.53, 24.53. FTIR 
(CHCl3 film): 3383.5, 3052.76, 1671.98, 1590.99, 1508.06, 1345.11, 1162.87 cm-1. HRMS: [M+H]+ 
calc. 500.1756, found 500.1755. 
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(S)-N-((R)-phenyl(pyridin-2-yl)methyl)-1-((4-(pyridin-4-yl)phenyl)sulfonyl)pyrrolidine-2-
carboxamide (215) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.74 – 8.62 (m, 3H), 8.56 (d, J = 4.8 Hz, 1H), 7.97 (d, J = 7.9 
Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.57 (t, J = 7.7 Hz, 1H), 7.48 (d, J = 5.1 Hz, 2H), 7.37 (d, J = 7.6 
Hz, 2H), 7.23 (q, J = 8.0 Hz, 3H), 7.14 (dt, J = 12.0, 6.8 Hz, 2H), 6.10 (d, J = 7.5 Hz, 1H), 4.24 (dd, 
J = 8.3, 2.9 Hz, 1H), 3.70 – 3.48 (m, 1H), 3.29 (td, J = 9.6, 9.2, 6.0 Hz, 1H), 2.13 (dd, J = 9.5, 5.7 
Hz, 1H), 1.77 (dt, J = 17.0, 8.3 Hz, 1H), 1.70 – 1.59 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 
170.16, 158.80, 150.54, 149.18, 146.14, 142.90, 141.22, 136.79, 128.65, 128.59, 127.86, 127.44, 
127.17, 122.41, 122.38, 121.67, 62.59, 57.79, 49.78, 30.39, 24.42. FTIR (CHCl3 film): 1672.95, 
1590.99, 1506.13, 1348, 1161.9 cm-1. HRMS: [M+H]+ calc. 499.1804, found 499.1790. 
 
 
 
 
 
 
 
 
124 
 
(3R,5S)-5-(((R)-phenyl(pyridin-2-yl)methyl)carbamoyl)-1-((4-(pyridin-3-yl)phenyl) 
sulfonyl)pyrrolidin-3-yl acetate (216) 
 
 
 
 
 
 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.83 (dd, J = 2.4, 0.9 Hz, 1H), 8.67 (dd, J = 4.8, 1.6 Hz, 1H), 
8.60 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 8.56 (d, J = 7.3 Hz, 1H), 7.99 (d, J = 8.7 Hz, 2H), 7.87 (ddd, J 
= 7.9, 2.4, 1.6 Hz, 1H), 7.70 (d, J = 8.7 Hz, 2H), 7.62 (td, J = 7.7, 1.8 Hz, 1H), 7.42 (ddd, J = 8.0, 
4.8, 0.9 Hz, 1H), 7.40 – 7.37 (m, 2H), 7.32 – 7.26 (m, 2H), 7.25 – 7.17 (m, 3H), 6.10 (d, J = 7.3 Hz, 
1H), 5.09 (dh, J = 4.4, 2.0 Hz, 1H), 4.41 (t, J = 8.1 Hz, 1H), 3.79 (dd, J = 13.0, 4.1 Hz, 1H), 3.71 
(dt, J = 13.0, 1.7 Hz, 1H), 2.37 – 2.23 (m, 2H), 1.61 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 
169.98 , 169.77, 149.93, 149.27, 148.28, 142.80, 137.00, 136.64, 134.59, 129.12, 128.75, 127.81, 
127.67, 127.40, 123.98, 122.67, 122.63, 72.63, 61.73, 57.88, 54.90, 37.10, 20.67. FTIR (CHCl3 
film): 3370, 3059.03, 2926.93, 2247.15, 1738.51, 1673.91, 1515.29, 1349.93, 1162.87 cm -1. 
HRMS: [M+H]+ calc. 557.1859, found 557.1857. 
 
 
 
 
 
 
 
125 
 
(2S,4R)-4-hydroxy-N-((R)-phenyl(pyridin-2-yl)methyl)-1-((4-(pyridin-3-yl)phenyl)sulfonyl) 
pyrrolidine-2-carboxamide (217) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.79 – 8.74 (m, 1H), 8.64 – 8.55 (m, 3H), 7.97 (d, J = 8.7 Hz, 
2H), 7.86 (dddd, J = 7.6, 5.2, 2.4, 1.6 Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.42 – 7.36 (m, 3H), 7.33 
(tt, J = 6.4, 1.3 Hz, 1H), 7.31 – 7.27 (m, 2H), 7.25 – 7.14 (m, 3H), 6.09 (d, J = 7.2 Hz, 1H), 4.44 – 
4.34 (m, 1H), 4.32 (p, J = 3.9 Hz, 1H), 3.66 (ddd, J = 11.3, 8.7, 4.3 Hz, 1H), 3.45 (d, J = 2.1 Hz, 
1H), 2.15 (tdd, J = 19.4, 6.9, 4.7 Hz, 1H), 2.09 – 1.99 (m, 1H). 13C NMR (126 MHz, Chloroform-d) 
δ 170.52, 158.82, 149.51, 149.26, 148.20, 137.08, 136.22, 134.96, 134.89, 129.16, 128.87, 128.78, 
127.73, 127.69, 127.38, 123.98, 122.69, 122.66, 69.72, 61.58, 57.98, 39.63, 29.82. FTIR (CHCl3 
film): 3353.05, 2924.52, 2853.65, 1668.12, 1515.78, 1338.84, 1159.97 cm-1. HRMS: [M+Na]+ calc. 
537.1572, found 537.1568. 
 
 
 
 
 
 
 
126 
 
(S)-5-oxo-N-((R)-phenyl(pyridin-2-yl)methyl)-1-((4-(pyridin-3-yl)phenyl)sulfonyl) 
pyrrolidine-2-carboxamide (218) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.84 (s, 1H), 8.67 (s, 1H), 8.62 (d, J = 4.8 Hz, 1H), 8.22 (d, J 
= 6.5 Hz, 1H), 8.11 (d, J = 8.3 Hz, 2H), 7.88 (dt, J = 7.9, 1.9 Hz, 1H), 7.68 (td, J = 7.7, 1.8 Hz, 1H), 
7.62 (d, J = 8.3 Hz, 2H), 7.42 (dd, J = 7.9, 4.7 Hz, 1H), 7.36 – 7.27 (m, 5H), 7.25 – 7.20 (m, 1H), 
6.11 (d, J = 6.5 Hz, 1H), 4.93 (dd, J = 6.7, 2.1 Hz, 1H), 2.74 – 2.60 (m, 1H), 2.46 – 2.31 (m, 2H), 
2.09 (td, J = 10.1, 2.5 Hz, 1H).13C NMR (126 MHz, Chloroform-d) δ 173.52, 169.04, 157.95, 149.74, 
149.02, 148.48, 143.57, 141.41, 137.33, 137.29, 134.90, 129.97, 128.98, 127.97, 127.41, 127.39, 
123.93, 122.95, 122.84, 60.85, 57.81, 30.87, 24.08. FTIR (CHCl3 film): 2925.48, 1741.89, 1682.59, 
1360.53, 1169.62 cm-1. HRMS: [M+H]+ calc. 513.1597, found 513.1595. 
 
 
 
 
 
 
 
 
 
 
127 
 
(S)-N-((R)-phenyl(pyridin-2-yl)methyl)-1-((4-(pyridin-3-yl)phenyl)sulfonyl)piperidine-2-carboxamide 
(219) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 8.83 (d, J = 2.3 Hz, 1H), 8.66 (dd, J = 4.8, 1.6 Hz, 1H), 8.57 
(ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 8.46 (d, J = 7.2 Hz, 1H), 8.00 (d, J = 8.6 Hz, 2H), 7.87 (ddd, J = 7.9, 
2.4, 1.6 Hz, 1H), 7.66 (d, J = 8.6 Hz, 3H), 7.60 (td, J = 7.7, 1.8 Hz, 1H), 7.41 (ddd, J = 7.9, 4.9, 0.8 
Hz, 1H), 7.22 (d, J = 4.3 Hz, 3H), 7.18 (dddd, J = 11.1, 6.4, 2.4, 1.4 Hz, 3H), 6.03 (d, J = 7.3 Hz, 
1H), 4.62 (d, J = 4.2 Hz, 1H), 4.04 (ddd, J = 14.0, 4.0, 2.1 Hz, 1H), 3.24 (ddd, J = 14.1, 12.4, 3.0 
Hz, 1H), 2.34 – 2.26 (m, 1H), 1.81 (s, 1H), 1.56 (q, J = 3.4 Hz, 1H), 1.52 – 1.45 (m, 1H), 1.43 – 
1.31 (m, 2H), 1.28 – 1.22 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 168.63, 158.68, 149.76, 
149.00, 148.43, 142.27, 141.59, 140.03, 136.97, 134.67, 132.25, 128.78, 128.20, 127.93, 127.70, 
127.37, 123.87, 122.73, 122.61, 57.63, 56.42, 43.66, 25.07, 24.17, 20.09. FTIR (CHCl3 film): 
3374.34, 2924.52, 2853.17, 1674.39, 1495.53, 1337.39, 1159.49 cm-1.  HRMS: [M+H]+ calc. 
513.1960, found 513.1960. 
 
 
 
 
 
 
 
128 
 
(S)-2-([1,1'-biphenyl]-4-sulfonamido)-N-benzylpropanamide (220) 
 
 
1H NMR (500 MHz, DMSO-d6) δ 8.39 (t, J = 5.9 Hz, 1H), 8.11 (s, 1H), 7.87 (d, J = 1.8 Hz, 4H), 7.74 
(dd, J = 8.2, 1.4 Hz, 2H), 7.57 – 7.49 (m, 2H), 7.47 – 7.40 (m, 1H), 7.26 (t, J = 7.5 Hz, 2H), 7.22 – 
7.17 (m, 1H), 7.17 – 7.12 (m, 2H), 4.22 – 4.09 (m, 2H), 3.85 (d, J = 7.2 Hz, 1H), 1.12 (d, J = 7.1 
Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 171.77, 144.35, 140.47, 139.63, 139.10, 129.72, 129.08, 
128.81, 127.81, 127.74, 127.64, 127.63, 127.32, 52.50, 42.59, 19.77. FTIR (CHCl3 film): 3231.63, 
1647.39, 1327.27, 1159.49, 1095.85 cm-1. HRMS: [M+H]+ calc. 395.1429, found 395.1431. 
 
 
 
 
 
 
 
 
 
 
 
 
129 
 
(S)-2-([1,1'-biphenyl]-4-sulfonamido)-N-benzyl-3-phenylpropanamide (221) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 7.69 (dd, J = 8.3, 1.2 Hz, 2H), 7.62 – 7.56 (m, 4H), 7.51 (dd, J 
= 8.3, 7.0 Hz, 2H), 7.47 – 7.41 (m, 1H), 7.29 – 7.21 (m, 3H), 7.19 – 7.14 (m, 1H), 7.14 – 7.08 (m, 
4H), 6.98 – 6.92 (m, 2H), 6.72 (t, J = 5.8 Hz, 1H), 5.36 (d, J = 7.0 Hz, 1H), 4.33 (d, J = 5.9 Hz, 2H), 
4.00 (q, J = 6.9 Hz, 1H), 3.06 – 2.91 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 170.26, 145.86, 
139.17, 137.51, 137.33, 135.40, 129.27, 129.24, 129.00, 128.75, 128.74, 127.82, 127.72, 127.60, 
127.37, 127.31, 58.31, 43.74, 38.71. FTIR (CHCl3 film): 3398.92, 1652.21, 1330.16, 1162.38 cm-1. 
HRMS: [M+H]+ calc. 471.1742, found 471.1735. 
 
 
 
 
 
 
 
 
 
 
 
130 
 
(S)-2-([1,1'-biphenyl]-4-sulfonamido)-N-benzyl-4-methylpentanamide (222) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 8.7 Hz, 2H), 7.68 (d, J = 8.7 Hz, 2H), 7.61 – 7.56 
(m, 2H), 7.51 – 7.46 (m, 2H), 7.46 – 7.41 (m, 1H), 7.26 – 7.20 (m, 3H), 7.17 – 7.05 (m, 2H), 6.48 
(t, J = 5.8 Hz, 1H), 5.48 (d, J = 7.6 Hz, 1H), 4.32 – 4.16 (m, 2H), 3.77 (ddd, J = 9.4, 7.5, 4.4 Hz, 
1H), 1.65 – 1.41 (m, 3H), 0.84 (d, J = 6.4 Hz, 3H), 0.68 (d, J = 6.2 Hz, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 171.47, 137.55, 129.23, 128.82, 128.76, 127.97, 127.82, 127.74, 127.69, 127.42, 
55.76, 43.77, 42.60, 24.49, 23.12, 21.34. FTIR (CHCl3 film): 3281.29, 2956.82, 1652.21, 1325.82, 
1162.87 cm-1.  HRMS: [M+H]+ calc. 437.1899, found 437.1899. 
 
 
 
 
 
 
 
 
 
 
 
131 
 
(S)-2-([1,1'-biphenyl]-4-sulfonamido)-N-benzyl-3-(4-hydroxyphenyl)propanamide (223) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 7.75 – 7.67 (m, 3H), 7.66 (s, 5H), 7.50 (t, J = 7.5 Hz, 2H), 7.44 
(td, J = 7.2, 6.3, 2.8 Hz, 1H), 7.27 (s, 2H), 7.16 – 7.13 (m, 2H), 6.77 (d, J = 8.3 Hz, 2H), 6.58 (d, J 
= 8.3 Hz, 2H), 4.99 (d, J = 6.7 Hz, 1H), 4.45 – 4.29 (m, 2H), 3.88 (q, J = 6.7 Hz, 1H), 3.05 – 2.81 
(m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 170.23, 155.20, 137.11, 130.44, 129.32, 128.86, 
128.83, 127.85, 127.81, 127.73, 127.45, 127.04, 115.96, 58.32, 43.85, 37.80. FTIR (CHCl3 film): 
3297.68, 2924.04, 1652.21, 1515.78, 1330.16, 1161.42 cm-1. HRMS: [M-H]- calc. 485.1535, found 
485.1548. 
 
 
 
 
 
 
 
 
 
 
 
132 
 
(S)-4-(2-([1,1'-biphenyl]-4-sulfonamido)-3-(benzylamino)-3-oxopropyl)phenyl [1,1'-biphenyl]-4-
sulfonate (224) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 7.90 – 7.76 (m, 2H), 7.72 – 7.64 (m, 4H), 7.63 – 7.57 (m, 6H), 
7.52 – 7.38 (m, 7H), 7.26 – 7.17 (m, 3H), 7.14 – 7.05 (m, 2H), 6.92 – 6.85 (m, 2H), 6.82 – 6.76 (m, 
2H), 6.67 (t, J = 5.8 Hz, 1H), 5.34 (d, J = 7.4 Hz, 1H), 4.29 (d, J = 5.8 Hz, 2H), 3.95 (td, J = 7.6, 5.9 
Hz, 1H), 3.01 (dd, J = 14.1, 5.9 Hz, 1H), 2.88 (dd, J = 14.1, 7.9 Hz, 1H). 13C NMR (126 MHz, 
Chloroform-d) δ 169.93, 148.74, 147.30, 146.04, 138.93, 138.81, 137.35, 137.29, 134.72, 133.84, 
130.61, 129.27, 129.02, 128.84, 128.81, 127.83, 127.80, 127.72, 127.71, 127.69, 127.48, 127.44, 
122.78, 58.11, 43.80, 38.15. FTIR (CHCl3 film): 3292.86, 1651.73, 1504.69, 1373.07, 1153.22 cm-
1. HRMS: [M-H]- calc. 701.1780, found 701.1777. 
 
 
 
 
 
 
 
 
 
133 
 
(R)-1-([1,1'-biphenyl]-4-ylsulfonyl)-N-benzyl-4-oxoazetidine-2-carboxamide (225) 
 
1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J = 8.0 Hz, 2H), 7.67 (d, J = 8.3 Hz, 2H), 7.54 (d, J = 
7.3 Hz, 2H), 7.42 (dd, J = 8.3, 6.8 Hz, 2H), 7.38 – 7.33 (m, 1H), 7.27 – 7.17 (m, 4H), 4.56 (d, J = 
2.1 Hz, 2H), 4.18 (dd, J = 8.8, 5.7 Hz, 1H), 3.01 (dd, J = 18.4, 8.9 Hz, 1H), 2.68 (ddd, J = 18.3, 5.7, 
0.9 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 174.42, 173.84, 138.12, 135.07, 129.08, 128.79, 
128.71, 128.59, 128.20, 127.85, 127.67, 127.33, 51.49, 42.75, 37.01. FTIR (CHCl3 film): 3227.29, 
1704.76, 1351.37, 1146.47   cm-1. HRMS: [M-H]- calc. 419.1066, found 419.1078. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
134 
 
methyl (S)-3-([1,1'-biphenyl]-4-sulfonamido)-4-(benzylamino)-4-oxobutanoate (226) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 7.91 (dd, J = 8.3, 1.6 Hz, 2H), 7.78 – 7.67 (m, 2H), 7.67 – 7.54 
(m, 2H), 7.50 (ddd, J = 7.8, 6.3, 1.4 Hz, 2H), 7.47 – 7.39 (m, 1H), 7.31 – 7.21 (m, 4H), 7.20 – 7.12 
(m, 2H), 7.00 (s, 1H), 6.12 (d, J = 9.0 Hz, 1H), 4.48 – 4.30 (m, 2H), 4.15 (ddd, J = 9.5, 5.8, 3.8 Hz, 
1H), 3.62 (d, J = 1.2 Hz, 3H), 3.07 (ddd, J = 17.3, 3.9, 1.3 Hz, 1H), 2.40 (ddd, J = 17.2, 6.1, 1.5 Hz, 
1H). 13C NMR (126 MHz, Chloroform-d) δ 169.21, 137.55, 129.27, 128.89, 128.84, 128.12, 127.71, 
127.61, 127.46, 76.91, 53.58, 52.38, 43.94, 35.61. FTIR (CHCl3 film): 3377.23, 1739.48, 1668.12, 
1339.8, 1162.87 cm-1. HRMS: [M-H]- calc. 451.1328, found 451.1338. 
 
 
 
 
 
 
 
 
 
 
 
135 
 
methyl (S)-4-([1,1'-biphenyl]-4-sulfonamido)-5-(benzylamino)-5-oxopentanoate (227) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 7.93 – 7.83 (m, 2H), 7.70 – 7.63 (m, 2H), 7.62 – 7.55 (m, 2H), 
7.51 – 7.45 (m, 2H), 7.46 – 7.39 (m, 1H), 7.25 – 7.14 (m, 3H), 7.10 (dd, J = 7.7, 1.9 Hz, 2H), 6.78 
(t, J = 5.8 Hz, 1H), 6.26 (d, J = 7.5 Hz, 1H), 4.38 – 4.22 (m, 2H), 3.86 (ddd, J = 8.8, 7.5, 4.1 Hz, 
1H), 3.64 (s, 3H), 2.51 (ddd, J = 17.6, 8.8, 5.1 Hz, 1H), 2.28 (ddd, J = 17.7, 6.9, 5.0 Hz, 1H), 2.03 
– 1.95 (m, 1H), 1.90 (dddd, J = 14.3, 8.8, 6.9, 5.1 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 
129.21, 128.78, 128.75, 127.86, 127.79, 127.65, 127.62, 127.41, 77.41, 56.40, 52.19, 43.73, 29.73, 
28.25. FTIR (CHCl3 film): 3282.25, 1733.21, 1652.7, 1161.42, 1094.89 cm-1. HRMS: [M-H]- calc. 
465.1484, found 465.1495. 
 
 
 
 
 
 
 
 
 
 
136 
 
(S)-3-([1,1'-biphenyl]-4-ylsulfonyl)-N-(pyridin-2-ylmethyl)thiazolidine-2-carboxamide (229) 
 
1H NMR (500 MHz, Chloroform-d) δ 8.52 (dt, J = 4.9, 1.2 Hz, 1H), 7.95 (dd, J = 8.6, 2.2 Hz, 2H), 
7.82 (q, J = 5.4, 4.0 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.64 (td, J = 7.7, 1.8 Hz, 1H), 7.61 – 7.58 (m, 
2H), 7.49 – 7.45 (m, 2H), 7.44 – 7.38 (m, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.19 – 7.14 (m, 1H), 5.50 
(s, 1H), 4.59 (d, J = 5.3 Hz, 2H), 4.01 – 3.94 (m, 1H), 3.77 (ddd, J = 11.8, 7.2, 6.0 Hz, 1H), 3.00 
(dt, J = 11.1, 5.7 Hz, 1H), 2.59 (ddd, J = 11.0, 7.2, 6.0 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) 
δ 169.31, 156.20, 149.26, 138.92, 137.00, 135.24, 129.27, 128.95, 128.56, 128.15, 127.49, 122.57, 
121.88, 65.23, 53.06, 44.83, 31.53. FTIR (CHCl3 film): 3371.92, 3062.41, 2938.98, 2245.7, 
1682.59, 1520.11, 1352.82, 1165.28 cm-1. HRMS: [M+Na]+ calc. 462.0922, found 462.0923. 
 
 
 
 
 
 
 
 
 
 
 
137 
 
(S)-3-([1,1'-biphenyl]-4-ylsulfonyl)-N-benzylthiazolidine-2-carboxamide (230) 
 
 
1H NMR (500 MHz, Chloroform-d) δ 7.92 (d, J = 9.1 Hz, 2H), 7.75 (d, J = 8.3 Hz, 2H), 7.61 (dd, J 
= 8.1, 1.4 Hz, 2H), 7.49 (dd, J = 8.3, 6.6 Hz, 2H), 7.46 – 7.41 (m, 1H), 7.35 – 7.24 (m, 5H), 7.10 (t, 
J = 6.0 Hz, 1H), 5.45 (d, J = 5.0 Hz, 1H), 4.50 (t, J = 5.5 Hz, 2H), 3.92 (dt, J = 11.5, 5.7 Hz, 1H), 
3.70 (ddd, J = 11.8, 7.1, 6.0 Hz, 1H), 2.95 (dt, J = 11.1, 5.6 Hz, 1H), 2.53 (ddd, J = 11.1, 7.1, 6.0 
Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 169.24, 146.99, 138.89, 137.83, 134.93, 129.30, 
129.01, 128.91, 128.54, 128.22, 127.71, 127.69, 127.52, 65.34, 53.22, 43.89, 31.43. FTIR (CHCl3 
film): 3381.57, 3063.85, 3031.07, 2933.68, 2246.66, 1667.64, 1520.11, 1352.82, 1165.76 cm -1. 
HRMS: [M+Na]+ calc. 461.0970, found 461.0966. 
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